FDA Calendar

Biotech Catalyst and FDA Calendar for your biotech stock investing. Use our tools on your road to profit in the stock market. Biotech stocks with key binary events/catalysts - FDA Approval/PDUFA, Advisory Committee and Phase 2 & 3 trial data releases dates.

Refer to the Biotech Historical Catalyst Calendar for completed biotech catalysts.

The catalyst date is the LATEST expected date for the catalyst to occur by.  For example, if the catalyst date is 12/31/17, the event is expected to occur BY 12/31/17. It does NOT necessarily mean that the catalyst will occur ON this date. In most cases it will occur BEFORE.

Please refer to the "FDA Calendar Glossary" for a list of terms used in the FDA Decision Calendar.

LARGE cap companies are now listed. There is an ERROR with the financial data (e.g price change, volume, mkt cap etc). A new API is being sourced to rectify the issue.

LARGE CAP CATALYSTS - generally only Phase 3 catalysts noted in company presentations and/or earnings releases are shown.

PDUFA DATES - biosimilars and sNDA/sBLA filings and resubmissions are only noted if a PDUFA date has been released by the company. No official PDUFA date = No entry (e.g. Saxagliptin and dapagliflozin resubmission). Standard reviews for NDA/BLA filings use a 10 month estimate following filing acceptance for a NEW MOLECULAR ENTITY if no PDUFA date has been announced.

Pipeline data are current and updated daily! Click on the date for the source of the catalyst.

Financial data updated each evening.

Subscribe HERE to ensure you receive your weekly FREE copy of the BioPharmCatalyst Biotech Stock Watchlist and/or our daily option of Biotech Stock Price Movers and Pipeline Database updates

Showing 587 drugs
Ticker Price Drug Stage Catalyst
AUPH
$8.53
+0.16  (+1.91%)
Voclosporin - AURION trial
Lupus
Phase 2
48-week data from open-label AURION study to be presented on March 27, 2017
REGN
$369.14
-1.84  (-0.5%)
Dupixent (dupilumab)
Atopic dermatitis
PDUFA priority review
PDUFA date under priority review March 29, 2017.
SNY
$41.04
0  (0%)
Dupixent (dupilumab)
Atopic dermatitis
PDUFA priority review
PDUFA date under priority review March 29, 2017.
CARA
$16.09
+0.51  (+3.27%)
IV CR845
Uremic pruritus
Phase 2/3
Phase 2/3 completion of enrollment announced November 29, 2016 with top-line data due 1Q 2017.
CRBP
$9.25
-1.11  (-10.63%)
Anabasum (Resunab)
Cystic Fibrosis
Phase 2
Phase 2 data due by the end of March 2017.
MESO
$9.30
+0.6  (+6.9%)
MPC-150-IM
Chronic heart failure (CHF)
Phase 3
Phase 3 interim analysis 1Q 2017.
MRUS
$26.06
-2.44  (-8.56%)
MCLA-128
Breast cancer
Phase 1/2
Phase 1/2 interim data due 1Q 2017.
NVS
$71.95
0  (0%)
CTL019 - JULIET
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 3
Phase 2 pivotal primary analysis due 2Q 2017. Interim analysis 1Q 2017.
ONCE
$52.67
-5.37  (-9.25%)
SPK-7001 (SPK-CHM)
Choroideremia
Phase 1/2
Phase 1/2 dosing commenced 1Q 2015. Initial data due early 2017.
PGNX
$10.82
-0.47  (-4.16%)
Azedra
Pheochromocytoma
Phase 2b
Pivotal Phase 2 trial resumed January 2015 following suspension of trial in 2010 due to lack of funding. Enrollment completed by end of 2015.Top-line data due March 2017.
PTI
$11.20
-0.94  (-7.74%)
PTI-428
Cystic fibrosis
Phase 1
Phase 1 top-line data due 1Q 2017.
RTTR
$1.82
-0.04  (-2.15%)
RP-G28
Lactose intolerance
Phase 2/3
Phase 2/3 top-line data are due 1Q 2017.
XBIT
$16.82
+0.43  (+2.62%)
514G3
Staphylococcus Aureus Bacteremia
Phase 1/2
Phase 1/2 enrollment completed December 2016. Top-line data due 1Q 2017.
XENE
$8.40
+0.15  (+1.82%)
XEN801
Acne
Phase 2
Phase 2 initiated February 2016. Data due late 1Q 2017.
KPTI
$10.14
-0.53  (-4.97%)
Selinexor - SADAL
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2b
Phase 2b additional interim data due in Tuesday, April 4, 2017 at AACR - follows release of initial data on March 16, 2017. Final top-line data due mid-2018.
NLNK
$20.65
-1.75  (-7.81%)
Indoximod in combination with pembrolizumab
Melanoma - cancer
Phase 2
Phase 2 interim analysis due at AACR meeting Tuesday April 4, 2017.
GSK
$39.31
0  (0%)
MK-1293
Type 1 and type 2 diabetes
PDUFA
NDA filing acceptance announced August 5, 2016. Estimate PDUFA date April 5, 2017. Estimate based on 10 month review period following filing for a non-NME.
MRK
$61.37
0  (0%)
MK-1293
Type 1 and type 2 diabetes
PDUFA
NDA filing acceptance announced August 5, 2016. PDUFA date estimate April 5, 2017.
SNY
$41.04
0  (0%)
MK-1293
Type 1 and type 2 diabetes
PDUFA
NDA acceptance announcement August 5, 2016. PDUFA date estimate April 5, 2017.
NBIX
$41.77
-2.12  (-4.83%)
INGREZZA
Tardive dyskinesia
PDUFA
PDUFA date under priority review April 11, 2017. Announced January 5, 2017 that the Advisory Committee Meeting originally scheduled for February 16, 2016 has been cancelled.
CAPR
$3.18
+0.06  (+1.92%)
CAP-1002 HOPE-Duchenne
Duchenne Muscular Dystrophy (DMD)
Phase 1/2
Phase 1/2 enrollment completed September 2016 with data due EARLY 2Q 2017.
INCY
$140.73
-7.79  (-5.25%)
Baricitinib
Rheumatoid arthritis
PDUFA
Announced January 19 2016 NDA filing by partner Eli Lilly. Noted January 13 2017 that its PDUFA date has been extended three months. Estimate April 14, 2017.
LLY
$76.76
0  (0%)
Baricitinib
Rheumatoid arthritis
PDUFA
Announced January 19 2016 that NDA Filing had been submitted. Three month delay announced January 13, 2017. Estimate April 14 or April 17, 2017 PDUFA date.
PLX
$1.10
-0.05  (-4.35%)
AIR DNase (PRX-110)
Cystic Fibrosis
Phase 2
Phase 2 interim data released January 3, 2017. Full data due first half of April 2017. April 14 noted as estimated final possible date due to guidance of "first half April".
AUPH
$8.53
+0.16  (+1.91%)
Voclosporin - AURA trial
Lupus
Phase 2b
Phase 2b data released August 2016. Primary endpoint met but with high number of deaths. Further data released March 1, 2017 - no additional deaths and endpoints met. Oral presentation of data at National Kidney Foundation (NKF) 2017 Spring Clinical Meeting - 4pm April 20, 2017. Phase 3 trial to be initiated 2Q 2017.
PFE
$31.96
0  (0%)
IBRANCE (palbociclib)
HR+, HER2- Metastatic Breast Cancer
PDUFA priority review
sNDA acceptance announced December 21, 2016. PDUFA date estimate under priority review April 21, 2017.
AKTX
$6.52
+0.02  (+0.31%)
Coversin
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 2
Phase 2 interim data to be presented April 24, 2017
BMRN
$87.42
+0.39  (+0.45%)
Cerliponase alfa
Batten Disease
PDUFA
PDUFA date extended by three months to April 27 2017
AEZS
$2.70
-0.1  (-3.57%)
Zoptrex
Endometrial cancer
Phase 3
Noted January 30, 2017 completion of Phase 3 trial with data due April 2017.
NBIX
$41.77
-2.12  (-4.83%)
INGREZZA
Tourette syndrome - juvenile
Phase 2
Phase 2 data due April 2017.
NTRP
$18.90
+0.3  (+1.61%)
Bryostatin
Alzheimer's disease
Phase 2
Phase 2 data due April 2017. Announced conclusion of dosing and patient monitoring February 28, 2017.
BTX
$3.15
-0.1  (-3.08%)
OpRegen
Dry age-related macular degeneration (AMD)
Phase 1/2
Phase 2 second cohort underway. Data due May 7-11, 2017 at ARVO conference.
TXMD
$6.61
-0.27  (-3.92%)
Yuvvexy
Moderate-to-severe vaginal pain
PDUFA
PDUFA date May 7, 2017.
MRK
$61.37
0  (0%)
Keytruda
First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
PDUFA priority review
PDUFA date May 10, 2017. Priority review.
NVS
$71.95
0  (0%)
Midostaurin (PKC412)
Acute myeloid leukemia (AML)
PDUFA priority review
Priority review granted November 14, 2016. PDUFA date estimate May 14, 2017.
PRTK
$15.30
-1.11  (-6.71%)
Omadacycline
Community-acquired bacterial pneumonia (CABP)
Phase 3
Phase 3 completion of enrollment announced January 18, 2017. Data due early 2Q 2017. April 15, 2017 noted as last possible date given guidance of "early 2Q".
NVO
$36.19
0  (0%)
Nonacog beta pegol
haemophilia B
PDUFA
BLA filing announced May 16, 2016. PDUFA estimate May 16, 2017.
MRK
$61.37
0  (0%)
ISENTRESS
HIV-1
PDUFA
PDUFA date May 27, 2017.
CORI
$3.57
-0.06  (-1.65%)
Corplex Donepezil
Alzheimer's disease
Pilot bioequivalence initiated 4Q 2016. Data due May 2017. Pivotal trial to commence later in 2017, with data mid-2018.
BLUE
$86.30
+2.25  (+2.68%)
bb2121
Relapsed/refractory multiple myeloma
Phase 1
Phase 1 interim data released November 30, 2016 - 78% ORR. Pivotal trial to be initiated 2017. Updated data at ASCO 2017. Exact date TBC.
CELG
$123.37
-0.45  (-0.36%)
bb2121
Relapsed/refractory multiple myeloma
Phase 1
Phase 1 interim data released November 30, 2016 - 78% ORR. Pivotal trial to be initiated 2017. Updated data at ASCO 2017. Exact date TBC.
EPZM
$16.60
-0.6  (-3.49%)
Tazemetostat
Solid tumors - cancer
Phase 2
Phase 2 interim data due at ASCO 2017.
IMDZ
$6.55
-0.65  (-9.03%)
G100
Follicular non-Hodgkin Lymphoma - cancer
Phase 2
Phase 2 data at ASCO 2017.
IMDZ
$6.55
-0.65  (-9.03%)
CMB305
Cancer - solid tumors
Phase 2
Phase 2 data at ASCO 2017.
LPTX
$7.45
-0.06  (-0.8%)
DKN-01
Cholangiocarcinoma
Phase 1/2
Phase 1/2 enrollment complete. Update expected at ASCO 2017 - date TBC.
ALKS
$59.43
+2.06  (+3.61%)
Aristada
Schizophrenia
PDUFA
Approved October 5 2015. sNDA filed for 2-month option August 8 2016. PDUFA date estimate June 8, 2017.
AMGN
$167.45
+0.6  (+0.36%)
CHS-1701
Pegfilgrastim biosimilar
PDUFA
BLA submission announced August 9, 2016. PDUFA date estimate June 9, 2017.
AZN
$28.53
0  (0%)
Durvalumab
Bladder cancer
PDUFA priority review
BLA acceptance announced December 9, 2017. PDUFA under priority review. Estimate June 9, 2017.
CHRS
$22.55
+0.2  (+0.89%)
CHS-1701
Pegfilgrastim biosimilar
PDUFA
PDUFA date June 9, 2017.
MRK
$61.37
0  (0%)
KEYTRUDA
Microsatellite Instability-High Cancer
PDUFA priority review
PDUFA date March 8, 2017 extended to June 9, 2017 due to submission of extra data.
EPZM
$16.60
-0.6  (-3.49%)
Tazemetostat
Relapsed or refractory B-cell NHL
Phase 2
Phase 2 futility analysis completed September 6, 2016. Futher data due at The International Conference on Malignant Lymphoma (ICML) - June 14, 2017.
MRK
$61.37
0  (0%)
KEYTRUDA
First and Second line locally advanced or metastatic urothelial cancer - bladder cancer
PDUFA priority review
PDUFA date June 14, 2017.
ADMP
$4.45
+0.15  (+3.49%)
Epinephrine Pre-filled Syringe (PFS)
Emergency treatment of anaphylaxis.
PDUFA
CRL issued March 27 2015. CRL issued again June 6, 2016. NDA resubmission announced December 16, 2016. NDA acceptance announced January 19, 2017. No PDUFA date announced. PDUFA date estimate June 15, 2017 using 6-month time frame from resubmission.
MTZPY
$20.87
+0.14  (+0.68%)
Edaravone
Amyotrophic lateral sclerosis (ALS)
PDUFA
PDUFA date June 16, 2017
JNJ
$114.93
0  (0%)
DARZALEX (Daratumumab) + pomalidomide and dexamethasone
Relapsed or refractory multiple myeloma
PDUFA
PDUFA date June 17, 2017
NEOS
$6.65
-0.56  (-7.64%)
Cotempla XR-ODT
Attention deficit hyperactivity disorder (ADHD)
PDUFA
CRL issued November 2015. PDUFA date June 19, 2017.
NVS
$71.95
0  (0%)
Zykadia
First-line use in patients with ALK+ metastatic NSCLC
PDUFA priority review
Priority review granted February 22, 2017. PDUFA estimate for sNDA June 22, 2017 using 6-month timeline following receipt of sNDA.
PTLA
$37.98
-2.44  (-6.04%)
Betrixaban (The APEX Study)
Venous thromboembolism (VTE) Prevention
NDA Filing
PDUFA date under priority review June 24, 2017. Phase 3 data released March 2016 did not meet primary endpoint.
BLUE
$86.30
+2.25  (+2.68%)
LentiGlobin - HGB-207 Northstar-2
non-β0/β0 transfusion-dependent thalassemia (TDT)
Phase 3
Noted on December 14, 2016 that Phase 3 dosing has commenced. Early data due at EHA 2017. Exact date TBC.
HALO
$13.29
-1.13  (-7.77%)
Subcutaneous rituximab
Various blood cancers
PDUFA
PDUFA June 26, 2017.
ABBV
$61.79
0  (0%)
Imbruvica
First-line MCL (mantle cell lymphoma)
Phase 3
Phase 3 data due 1H 2017.
ABBV
$61.79
0  (0%)
Risankizumab
Psoriatic Arthritis
Phase 2b
Phase 2b data due 1H 2017.
ABBV
$61.79
0  (0%)
ABT-494
Crohn’s Disease
Phase 2b
Phase 2b data due 1H 2017.
ABBV
$61.79
0  (0%)
Rova-T (TRINITY)
Third-line Small Cell Lung Cancer
Phase 2
Phase 2 pivotal data due 1H 2017.
AERI
$45.40
+0.1  (+0.22%)
Roclatan - Mercury trials
Glaucoma
Phase 3
Phase 3 Mercury 1 data released September 14, 2016. Primary endpoint met. Mercury 2 trial data due 2Q 2017.
AFMD
$2.35
-0.1  (-4.08%)
AFM13
Hodgkin Lymphoma - Cancer
Phase 1b
Phase 1b update 1H 2017.
AGN
$233.99
-0.57  (-0.24%)
Botox
Depression
Phase 2
Phase 2 top-line data due 1H 2017.
AGN
$233.99
-0.57  (-0.24%)
Sarecycline
Severe acne vulgaris
Phase 3
Phase 3 data due 1H 2017.
ALDR
$20.85
+0.05  (+0.24%)
ALD403 - PROMISE 1
Frequent episodic migraine
Phase 3
Phase 3 PROMISE 1 topline data due 1H 2017.
ALKS
$59.43
+2.06  (+3.61%)
ALKS 6428
Opioid dependence
Phase 3
Phase 3 initated September 2015. Data due 1H 2017.
ALNY
$53.25
-0.96  (-1.77%)
Givosiran
Acute hepatic porphyrias
Phase 1
Phase 1 additional data due June 2017 with a Phase 3 trial to be initiated in late 2017.
ALXN
$120.08
+1.38  (+1.15%)
SBC-103
MPS IIIB
Phase 1/2
Phase 1/2 ongoing. 6 and 12 month data due 2017.
AMAG
$21.75
+0.35  (+1.64%)
Feraheme
Adults with iron deficiency anemia (IDA)
Phase 3
Phase 3 trial to be completed estimated 1H 2017. sNDA due mid 2017.
AMGN
$167.45
+0.6  (+0.36%)
KYPROLIS (ARROW)
Multiple Myeloma
Phase 3
Phase 3 trial initiated June 2015. Data due 2017. Estimate data 1H 2017 using clinicaltrials.gov data.
ARDX
$14.10
+0.8  (+6.02%)
Tenapanor
Constipation-predominant irritable bowel syndrome (IBS-C)
Phase 3
Phase 3 data due 2Q and 2H 2017, respectively, in each of its two Phase 3 trials.
ARGS
$0.87
+0.07  (+8.64%)
AGS-003
Early stage renal cell carcinoma (RCC) - cancer
Phase 2
Phase 2 trial initial data due 1H 2017.
AVEO
$0.84
-0  (-0.02%)
Tivozanib + Opdivo
Renal cell cancer (RCC)
Phase 1/2
Phase 1/2 initiation of dosing announced March 22, 2017. Phase 1 part of trial data due 1H 2017.
AZN
$28.53
0  (0%)
Tralokinumab
Severe, uncontrolled asthma
Phase 3
Phase 3 data due 1H 2017.
AZN
$28.53
0  (0%)
Durvalumab +/- tremelimumab (ARCTIC)
Lung cancer
Phase 3
Phase 3 data 1H 2017.
AZN
$28.53
0  (0%)
Acalabrutinib - ACE-LY-004
Relapsed or Refractory Mantle Cell Lymphoma
Phase 2
Phase 2 data 1H 2017.
AZRX
$3.64
-0.15  (-3.96%)
MS1819-SD
Exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis (CP)
Phase 2
Announced December 21, 2016 that Phase 2 enrollment has commenced. Initial data due 1H 2017.
BMY
$56.47
0  (0%)
CM-568 - Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 2
Phase 2 data due 1H 2017.
BMY
$56.47
0  (0%)
CM-511 – Opdivo + Yervoy
First-line Melanoma
Phase 3
Phase 3 data due 1H 2017.
BMY
$56.47
0  (0%)
CM-143 – Opdivo
Second-line Glioblastoma (GBM) cancer
Phase 3
Phase 3 data due 1H 2017.
BMY
$56.47
0  (0%)
CM-140 – Opdivo
Second-line Non-Hodgkin's Lymphoma (NHL)
Phase 3
Phase 3 data due 1H 2017.
BPMX
$0.50
+0  (+0.76%)
BPX-01
Acne
Phase 2b
Phase 2b completion of enrollment announced January 4, 2017. Data due 2Q 2017.
BVXV
$5.37
+0  (+0%)
M-001
Universal flu vaccine
Phase 2b
Phase 2b enrollment commenced March 2016. Last patient visit September, 2016. Data due in "coming months". Estimate 1H 2017.
CAPR
$3.18
+0.06  (+1.92%)
CAP-1002 ALLSTAR
Myocardial infarction (heart attack)
Phase 2
Phase 2 enrolling. 6 month data likely due 2Q 2017.
CARA
$16.09
+0.51  (+3.27%)
IV CR845
Acute pain
Phase 3
Phase 3 initiated September 2015. Placed on clinical hold February 2016. Clinical hold released April 2016 with enrollment resuming June 2016. Interim conditional power analysis due 2Q 2017.
CARA
$16.09
+0.51  (+3.27%)
CR845
Osteoarthritis (OA)
Phase 2b
Phase 2b trial initiated September, 2016. Data are due 2Q 2017.
CELG
$123.37
-0.45  (-0.36%)
Ozanimod - RADIANCE
Relapsing Multiple Sclerosis
Phase 3
Phase 3 data due 2Q 2017.
CELG
$123.37
-0.45  (-0.36%)
Demcizumab plus carboplatin and pemetrexed - DENALI
First-line non-squamous Non-small cell lung cancer (NSCLC)
Phase 2
Phase 2 data are 1H 2017. Announced November 1, 2016 that it has discontinued further enrollment.
CELG
$123.37
-0.45  (-0.36%)
Demcizumab plus Abraxane - YOSEMITE
First-line pancreatic cancer
Phase 2
Phase 2 data are due 1H 2017.
CLSN
$0.26
-0.02  (-5.39%)
GEN-1 OVATION
Ovarian cancer
Phase 1b
Phase 1b interim data released January 17, 2016 with final data due 2Q 2017.
CRIS
$2.80
-0.18  (-6.04%)
CUDC-907
Diffuse-large B-cell lymphoma (DLBCL)
Phase 2
Phase 2 initial data due 1H 2017.
CYTK
$12.20
-0.3  (-2.4%)
CK-2127107
Spinal muscular atrophy (SMA)
Phase 2
Phase 2 initiated January 2016. Enrollment to be completed 4Q 2016. Data are due 1H 2017.
CYTR
$0.41
-0.02  (-3.48%)
Aldoxorubicin
Relapsed/refractory small cell lung cancer
Phase 2b
Phase 2b data due 2Q 2017.
EIGR
$10.55
-0.7  (-6.22%)
Lonafarnib - LOWR HDV
Chronic hepatitis delta virus (HDV)
Phase 2
Phase 2 end of trial data due 2Q 2017. Meeting with FDA scheduled for 4Q 2017.
FOLD
$6.82
-0.44  (-6.13%)
ATB200
Pompe Disease
Phase 1/2
Phase 1/2 additional data released February 15, 2017. Further data due 2Q and 3Q 2017.
FOMX
$9.27
-0.5  (-5.12%)
FMX101
Acne
Phase 3
Phase 3 completion of enrollment announced late November 2016. Data are due 1H 2017.
GEMP
$11.66
+1.26  (+12.12%)
Gemcabene - COBALT-1
Homozygous Familial Hypercholesterolemia (HoFH)
Phase 2b
Phase 2b data due June 2017. Interim data released January 30, 2017.
GERN
$2.05
-0.06  (-2.84%)
Imetelstat - IMerge Study
Myelodysplastic syndromes
Phase 2/3
Announced mid-January 2016 that Phase 2 dosing has been initiated. Internal review conducted September 2016, trial to continue as planned. Internal review due 2Q 2017.
GERN
$2.05
-0.06  (-2.84%)
Imetelstat - IMbarkStudy
Myelofibrosis
Phase 2
Phase 2 clinical hold lifted Nov 2014. Phase 2 initiated September 2015. Internal review conducted September 2016. Low dose discontinued, high dose enrollment suspended. Next review 2Q 2016.
GLPG
$79.99
-2.15  (-2.62%)
GLPG1690 - FLORA
Idiopathic pulmonary fibrosis
Phase 2a
Phase 2a top-line data due 2Q 2017.
GTXI
$4.92
-0.12  (-2.38%)
Enobosarm
Breast cancer - advanced AR+ TNBC
Phase 2
Phase 2 prelim data from Stage 1 portion of trial due 2Q 2017.
GWPH
$119.06
-3.41  (-2.78%)
Epidiolex
Dravet Syndrome
Phase 3
Second Phase 3 trial initiated mid April 2015. Data due 2017.
IMGN
$3.61
-0.05  (-1.37%)
Mirvetuximab soravtansine - FORWARD II
Ovarian cancer and relapsed endometrial cancer
Phase 1/2
Phase 1b/2 initial data due 2Q 2017.
IONS
$38.24
-1.83  (-4.57%)
IONIS-TTRRx
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Phase 3
Phase 3 data due 2Q 2017.
JAZZ
$142.34
-0.61  (-0.43%)
JZP-110
Excessive sleepiness associated with narcolepsy
Phase 3
Phase 3 data due 2Q 2017.
JNCE
$22.93
-0.03  (-0.13%)
JTX-2011
Solid tumors - Cancer
Phase 1/2
Phase 1/2 trial initiated September 2017.Safety data due 1H 2017, preliminary efficacy data due 2H 2017.
JNJ
$114.93
0  (0%)
Imetelstat - IMerge Study
Myelodysplastic syndromes
Phase 2b
Announced mid-January 2016 that Phase 2 dosing has been initiated. Internal review conducted September 2016, trial to continue as planned. Internal review due 2Q 2017.
JNJ
$114.93
0  (0%)
Imetelstat - IMbarkStudy
Myelofibrosis
Phase 2
Phase 2 clinical hold lifted Nov 2014. Phase 2 initiated September 2015. Internal review conducted September 2016. Low dose discontinued, high dose enrollment suspended. Next review 2Q 2016
KURA
$8.45
-0.3  (-3.43%)
Tipifarnib
Relapsed or refractory peripheral T-cell lymphoma
Phase 2
Phase 2 top-line data due 1H 2017.
LIFE
$3.65
-0.05  (-1.35%)
Resolaris
Early onset facioscapulohumeral muscular dystrophy (FSHD)
Phase 1/2
Phase 1/2 data due 1H 2017.
LLY
$76.76
0  (0%)
Ramucirumab - RAINFALL
First-line gastric cancer
Phase 3
Phase 3 initial PFS data due 1H 2017 with OS data due 2018.
LLY
$76.76
0  (0%)
Galcanezumab
Migraine prevention
Phase 3
Phase 3 data due 1H 2017.
MESO
$9.30
+0.6  (+6.9%)
MSC-100-IV
acute graft versus host disease (aGVHD) in children
Phase 3
Phase 3 trial to be completed 1H 2017.
NEOT
$1.41
-0.07  (-4.16%)
LIPO-202
Reduction of localized fat deposits under the chin (submental fat)
Phase 2
Phase 3 endpoints not met December 2015. Phase 2 trial initiated December 23, 2016 with data due June 2017.
NKTR
$21.83
-0.29  (-1.27%)
Cipro DPI
Bronchiectasis
Phase 3
Phase 3 data due 1H 2017.
NLNK
$20.65
-1.75  (-7.81%)
Indoximod + gemcitabine and nab-paclitaxel
Pancreatic cancer
Phase 2
Phase 2 data due 1H 2017.
NOVN
$6.35
-0.18  (-2.76%)
SB208
Fungal infections
Phase 2
Phase 2 data due 2Q 2017.
NVS
$71.95
0  (0%)
ACZ885 (canakinumab) - CANTOS
CV risk reduction
Phase 3
Phase 3 data due 2Q 2017.
NVS
$71.95
0  (0%)
RTH258 (brolucizumab)
Neovascular AMD
Phase 3
Phase 3 data due 1H 2017.
OMED
$9.36
-0.34  (-3.51%)
Demcizumab plus Abraxane - YOSEMITE
First-line pancreatic cancer
Phase 2
Phase 2 data are due 1H 2017.
OMED
$9.36
-0.34  (-3.51%)
Demcizumab plus carboplatin and pemetrexed - DENALI
First-line non-squamous Non-small cell lung cancer (NSCLC)
Phase 2
Phase 2 data are 1H 2017. Announced November 1, 2016 that it has discontinued further enrollment.
OMED
$9.36
-0.34  (-3.51%)
Tarextumab - PINNACLE trial
Small cell lung cancer
Phase 2
Phase 2 enrollment completed August 2016. Data due 1H 2017.
ONCE
$52.67
-5.37  (-9.25%)
SPK-9001
Hemophilia B
Phase 1/2
Phase 1/2 updated data at ASH 2016. Further update due 1H 2017.
OPK
$7.86
-0.15  (-1.75%)
Factor VIIa-CTP
Hemophilia
Phase 2
Phase 2 safety data due 1H 2017.
PBYI
$40.25
-4.2  (-9.45%)
Neratinib
HER2-positive metastatic breast cancer patients with brain metastases
Phase 2
Phase 2 data due 2Q 2017.
PBYI
$40.25
-4.2  (-9.45%)
PB272 (NSABP FB-7)
Neoadjuvant treatment for patients with HER2-positive breast cancer
Phase 2
Phase 2 biomarker data released December 7, 2016. Further interim data due 2Q 2017.
PBYI
$40.25
-4.2  (-9.45%)
Neratinib SUMMIT
HER2 non-amplified breast cancer that has a HER2 mutation
Phase 2
Phase 2 preliminary data released December 8, 2016. Further data due 2Q 2017.
PBYI
$40.25
-4.2  (-9.45%)
Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL
Extended adjuvant treatment of early stage HER2-positive breast cancer
Phase 2
Phase 2 additional data released December 8 2016. Noted high rates of diarrhea. Further data due 2Q 2017.
PBYI
$40.25
-4.2  (-9.45%)
Neratinib
Third-line HER2-positive metastatic breast cancer
Phase 3
Phase 3 data due 1H 2017.
PIRS
$2.52
-0.15  (-5.62%)
PRS-080
Anemia of chronic disease
Phase 1b
Phase 1b multiple ascending dose phase to be completed 2Q 2017. Phase 2a trial to be initiated 2Q 2017 with trial to be completed by the end of 2017.
PRTK
$15.30
-1.11  (-6.71%)
Omadacycline - oral
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 3
Phase 3 data due 2Q 2017.
PRTK
$15.30
-1.11  (-6.71%)
Sarecycline
Severe acne vulgaris
Phase 3
Phase 3 data due 1H 2017.
PSDV
$1.70
-0.01  (-0.58%)
Medidur
Posterior uveitis
NDA Filing
Phase 3 data released December 2015. Second Phase 3 trial data and NDA filing due 1H 2017.
RARE
$77.72
-7.35  (-8.64%)
rhGUS
Mucopolysaccharidosis 7 (MPS 7)
BLA Filing
Phase 3 data released July 2016. Primary endpoint hit. Secondary missed. BLA filing due 1H 2017.
RARE
$77.72
-7.35  (-8.64%)
KRN23
X-Linked Hypophosphatemia (XLH) - adult
Phase 3
Phase 3 enrolment completed July 2016. Data due 1H 2017.
RDHL
$10.37
-0.05  (-0.48%)
RIZAPORT (RHB-103)
Migraine
NDA Filing
Planned resubmission of NDA due 1H 2017.
RDHL
$10.37
-0.05  (-0.48%)
BEKINDA -GUARD
Gastroenteritis
Phase 3
Phase 3 enrollment of final patient announced February 13, 2017 with top-line data due 2Q 2017.
RDUS
$35.63
-2.59  (-6.78%)
RAD1901
Vasomotor symptoms
Phase 2b
Phase 2b data due 1H 2017.
RDUS
$35.63
-2.59  (-6.78%)
Abaloparatide-SC
Osteoporosis
PDUFA
PDUFA date originally scheduled for March 30 2017 delayed by three months to June 30, 2017.
RVNC
$19.55
-0.95  (-4.63%)
RT002
Cervical dystonia
Phase 2
Phase 2 full data due 2Q 2017.
RXDX
$8.35
-0.56  (-6.18%)
STARTRK-2 entrectinib
Solid tumors - cancer
Phase 2
Phase 2 trial initiated September 2015. Interim data due 2Q 2017.
RXII
$0.74
-0.01  (-0.41%)
Samcyprone - RXI-SCP-1502
Cutaneous warts
Phase 2
Phase 2 first cohort data due 2Q 2017. Full data due 2H 2017.
SAGE
$63.77
-4.63  (-6.77%)
SAGE-217
Parkinson’s disease (PD)
Phase 2
Phase 2 initiation announced December 13, 2016. Data from Part A of trial due 1H 2017.
SAGE
$63.77
-4.63  (-6.77%)
SAGE-547
SRSE
Phase 3
Phase 3 data due 1H 2017.
SBPH
$9.33
-0.73  (-7.26%)
SB 9200
Hepatitis B (HBV)
Phase 2a
Phase 2a data due 2Q 2017.
SELB
$10.95
-1.37  (-11.12%)
SEL-212
Tophaceous gout
Phase 2
Phase 2 dosing commenced late October 2016. Initial data due 1H 2017.
SNDX
$13.23
-1.04  (-7.29%)
Entinostat plus Keytruda - ENCORE 601
Recurrent non-small cell lung cancer (NSCLC)
Phase 1/2
Phase 2 enrolling as of November 2016. Go/no go decision to progress into the second stage due 1H 2017.
TSRO
$155.78
+6.11  (+4.08%)
Niraparib - NOVA (Niraparib Ovarian)
Cancer - ovarian
PDUFA priority review
Phase 3 data met endpoints - June 2016. PDUFA date under priority review is June 30, 2017. No advisory committee meeting planned.
VRTX
$89.50
-1.81  (-1.98%)
VX-661
Cystic fibrosis - Two Copies of the F508del Mutation
Phase 3
Phase 3 data due 1H 2017.
VRTX
$89.50
-1.81  (-1.98%)
VX-661
Cystic fibrosis - One Copy of the F508del Mutation and a Second Mutation that Results in Residual CFTR Function
Phase 3
Phase 3 data due 1H 2017.
VRX
$10.71
-0.01  (-0.09%)
SAN-300
Rheumatoid Arthritis
Phase 2
Phase 2 data due 1H 2017.
ZYNE
$7.30
+0  (+0%)
ZYN002
Fragile X syndrome
Phase 2
Phase 2 trial initiation announced January 3, 2017. Data are due late 1H 2017.
AMGN
$167.45
+0.6  (+0.36%)
EVENITY (Romosozumab)
Osteoporosis
PDUFA
PDUFA date July 19, 2017.
OCUL
$9.17
-0.7  (-7.09%)
DEXTENZA
Ocular inflammation and pain following cataract surgery
PDUFA
CRL July 25 2016 - due to manufacturing deficiencies. NDA resubmitted, PDUFA date July 19, 2017.
PBYI
$40.25
-4.2  (-9.45%)
PB272 ExteNET trial
Extended adjuvant HER2-positive early stage breast cancer
PDUFA
Announced acceptance of NDA Filing September 20, 2016. PDUFA estimate July 20, 2017.
GSK
$39.31
0  (0%)
Benlysta (belimumab) - subcutaneous
Systemic lupus erythematosus (SLE)
PDUFA
BLA filing announced September 23, 2016. PDUFA estimate July 23, 2017.
ALNY
$53.25
-0.96  (-1.77%)
Patisiran APOLLO
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 3
Phase 3 data due mid 2017.
ARNA
$1.43
-0.01  (-0.69%)
Ralinepag
Pulmonary Arterial Hypertension
Phase 2
Phase 2 data due mid-2017.
ATNM
$1.41
+0.01  (+0.71%)
Actimab-A
Acute Myeloid Leukemia (AML)
Phase 2
Phase 2 initiated September 2016. Interim analysis due mid-2017.
AVEO
$0.84
-0  (-0.02%)
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer
Phase 3
Phase 3 enrollment to be completed June 2017. Futility analysis due mid-2017. Top-line data due 1Q 2018.
AZN
$28.53
0  (0%)
Durvalumab +/- tremelimumab (MYSTIC)
Lung cancer
Phase 3
Phase 3 PFS data mid-2017 and final OS data at the latest in 2018.
BLPH
$1.32
-0.09  (-6.38%)
INOpulse delivery device
Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF)
Phase 2
Phase 2 initiated May 2016. Data due mid-2017.
BLPH
$1.32
-0.09  (-6.38%)
INOpulse delivery device
Pulmonary Hypertension associated with COPD (PH-COPD)
Phase 2
Phase 2 initiated 3Q 2016. Data due mid-2017.
BTX
$3.15
-0.1  (-3.08%)
Renevia
Restoring normal skin contours in for patients with HIV
Phase 3
Pivotal trial data due by mid-2017.
CLVS
$67.18
+2.58  (+3.99%)
Rucaparib ARIEL3
Ovarian cancer patients with a BRCA-like mutation
Phase 3
Pivotal trial initiated late 2013. Enrollment completed 2Q 2016. Data due mid-2017.
FOLD
$6.82
-0.44  (-6.13%)
SD-101
Epidermolysis Bullosa (EB)
Phase 3
"Phase 3 top-line data due mid 2017.
GILD
$71.93
0  (0%)
Bictegravir/F/TAF
HIV/AIDS
Phase 3
Phase 3 data due mid-2017 with possible NDA filing 3Q 2017.
IRWD
$16.95
-0.66  (-3.75%)
IW-3718
Gastroesophageal reflux disease (GERD)
Phase 2b
Phase 2b data due mid-2017.
ITEK
$1.65
-0.1  (-5.71%)
Trabodenoson and latanoprost
Glaucoma
Phase 2
Phase 2 initiated July 2016. Data due mid-2017.
JNJ
$114.93
0  (0%)
INVOKANA CANVAS
Type 2 diabetes
Phase 3
Cardiovascular Outcomes trial data due mid-2017.
KMDA
$6.98
+0.02  (+0.37%)
Alpha-1 Antitrypsin (AAT)
Pediatric patients newly diagnosed with type 1 diabetes
Phase 2/3
Phase 2/3 data due mid-2017.
KPTI
$10.14
-0.53  (-4.97%)
Selinexor - SEAL
Dedifferentiated liposarcoma
Phase 2/3
Phase 2/3 trial initiated January 2016. Top-line data for the Phase 2 portion due mid-2017.
LXRX
$13.98
-0.86  (-5.8%)
Sotagliflozin
Type 1 Diabetes
Phase 3
Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial due mid-2017.
MEIP
$1.58
-0.03  (-1.86%)
ME-401
Chronic lymphocytic leukemia/small lymphocytic lymphoma or follicular lymphoma
Phase 1b
Phase 1b data due mid-2017.
MRK
$61.37
0  (0%)
Anacetrapib (MK-0859)
Raising HDL-C and reducing LDL-C
Phase 3
Phase 3 data due mid-2017.
MRNS
$1.45
-0.08  (-4.62%)
Ganaxolone
CDKL5 disorder
Phase 2
Phase 2 preliminary CDKL5 cohort data released January 23, 2017. Top-line data due mid-2017.
NKTR
$21.83
-0.29  (-1.27%)
NKTR-214
Solid tumors - cancer
Phase 1/2
Phase 1/2 initial data due mid-2017.
NKTR
$21.83
-0.29  (-1.27%)
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3
Phase 3 data due mid-2017.
ONCE
$52.67
-5.37  (-9.25%)
SPK-8011
Hemophilia A
Phase 1/2
Phase 1/2 trial to be initiated 4Q 2016 with initial data due mid 2017.
PRQR
$4.55
-0.1  (-2.15%)
QR-010
Cystic Fibrosis
Phase 1b
Phase 1b top-line data due mid-2017. Open label data presented at (NACFC) October 27, 2016.
RDHL
$10.37
-0.05  (-0.48%)
RHB-104 MAP US
Crohn’s disease
Phase 3
Phase 3 DSMB safety analysis released December 13, 2016 - trial to continue as planned. Interim efficacy analysis due mid-2017.
RDHL
$10.37
-0.05  (-0.48%)
BEKINDA
IBS-D
Phase 2
Phase 2 top-line data due mid 2017.
RETA
$26.46
-0.87  (-3.18%)
Omaveloxolone - MOXIe
Friedreich’s ataxia (FA)
Phase 2
Phase 2 initial data due mid-2017.
RNN
$0.42
-0.05  (-8.98%)
RX-3117
Advanced bladder cancer
Phase 2a
Phase 2a initial data due mid-2017.
RNN
$0.42
-0.05  (-8.98%)
Archexin
Renal cell carcinoma (RCC) - cancer
Phase 2a
Phase 2a second stage enrollment commenced February 2016. Data due mid-2017.
RXII
$0.74
-0.01  (-0.41%)
RXI-109-1402
Connective tissue growth factor (CTGF)
Phase 2
Phase 2 final readout due mid 2017.
SNY
$41.04
0  (0%)
Fitusiran (ATLAS)
Hemophilia
Phase 3
Phase 3 program to be initiated 2Q 2017, with initial data due mid-late 2017.
SNY
$41.04
0  (0%)
Patisiran APOLLO
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 3
Phase 3 top-line data due mid-2017.
SNY
$41.04
0  (0%)
Sotagliflozin
Type 1 Diabetes
Phase 3
Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial due mid-2017.
TBPH
$31.86
-1.87  (-5.54%)
Revefenacin
COPD
Phase 3
Phase 3 trials met primary endpoint. 12 month safety trial data (mid-2017) and NDA filing end of 2017.
TBPH
$31.86
-1.87  (-5.54%)
Velusetrag (TD-5108)
Gastroparesis
Phase 2b
Phase 2b initiated mid March 2015. Completion of study due mid-2017.
TGTX
$11.75
-1.5  (-11.32%)
TG-1101 and TGR-1202 - UNITY-DLBCL study
Diffuse large B-cell lymphoma (DLBCL) cancer
Phase 2b
Phase 2b enrollment commenced June 2016. First interim analysis due mid-2017.
VBLT
$5.70
-0.2  (-3.39%)
VB-111
Recurrent glioblastoma (rGBM) cancer
Phase 3
Phase 3 completion of enrollment announced January 6, 2017. Interim analysis due mid 2017. Full data due early 2018.
VKTX
$1.24
-0.05  (-3.88%)
VK5211
Acute Hip Fracture
Phase 2
Phase 2 to be completed mid-2017.
VNDA
$13.90
-0.25  (-1.77%)
VLY-686 (tradipitant)
Chronic pruritus in patients with atopic dermatitis
Phase 2
Phase 2 data due in mid-2017.
VSTM
$1.54
-0.08  (-4.95%)
Duvelisib - DUO
Cancer - relapsed/refractory chronic lymphocytic leukemia (CLL)
Phase 3
Phase 3 data due mid-2017.
VYGR
$10.91
-0.54  (-4.72%)
VY-AADC01
Advanced Parkinson’s disease
Phase 1b
Phase 1b trial onoging. Interim data released December 7, 2016. Cohort 3 data due mid-2017. Placebo-controlled trial to commence 4Q 2017.
WINT
$1.20
-0.04  (-3.23%)
Aerosurf
Respiratory Distress Syndrome - premature infants 26 to 32 weeks
Phase 2b
Announced October 25, 2016 data delay. Phase 2b top-line data now due mid 2017.
XENE
$8.40
+0.15  (+1.82%)
TV-45070
Postherpetic neuralgia
Phase 2b
Phase 2b initiated late March 2015. Data due mid-2017.
ABBV
$61.79
0  (0%)
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
PDUFA priority review
Priority review granted February 2, 2017. No PDUFA date supplied. Estimate August 2, 2017.
ENTA
$28.50
-0.7  (-2.4%)
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
PDUFA priority review
Priority review granted February 2, 2017. No PDUFA date supplied. Estimate August 2, 2017.
DVAX
$5.65
-0.35  (-5.83%)
HEPLISAV-B
Hepatitis B
PDUFA
CRL February 25, 2013 and November 14, 2016. New PDUFA date August 10, 2017
ALNY
$53.25
-0.96  (-1.77%)
ALN-HBV
Chronic hepatitis B virus (HBV)
Phase 1/2
Phase 1/2 trial initiated July 2016. Data are due mid 2017
PFE
$31.96
0  (0%)
Inotuzumab Ozogamicin
Relapsed or Refractory Acute Lymphoblastic Leukemia in Adults
PDUFA priority review
Priority review announced February 21, 2016. Estimate PDUFA date August 21, 2017 at latest. Possibly earlier as NDA acceptance was announced following 3-day weekend.
ADMS
$17.47
+0.24  (+1.39%)
ADS-5102
Levodopa-Induced Dyskinesia
PDUFA
PDUFA date August 24, 2017.
VRX
$10.71
-0.01  (-0.09%)
Latanoprostene bunod
Open angle glaucoma (OAG) or ocular hypertension (OHT)
PDUFA
PDUFA date August 24, 2017 (resubmission)
MRK
$61.37
0  (0%)
Avelumab
Urothelial Carcinoma
PDUFA priority review
PDUFA date August 27, 2017 under priority review.
PFE
$31.96
0  (0%)
Avelumab
Urothelial Carcinoma
PDUFA priority review
PDUFA date August 27, 2017 under priority review.
KMDA
$6.98
+0.02  (+0.37%)
KamRAB
Prophylaxis of rabies disease
PDUFA
PDUFA date August 29, 2017.
AGIO
$52.92
-0.23  (-0.43%)
Enasidenib (AG-221)
Advanced hematologic malignancies with an IDH2 mutation
PDUFA priority review
PDUFA date August 30, 2017 under priority review.
CELG
$123.37
-0.45  (-0.36%)
Enasidenib (AG-221)
Relapsed/Refractory IDH2 mutant-positive Acute Myeloid Leukemia -
PDUFA priority review
PDUFA date August 30, 2017 under priority review.
ZYNE
$7.30
+0  (+0%)
ZYN002
Osteoarthritis
Phase 2
Phase 2 initiated September 2016. Data are due July or August 2017.
ZYNE
$7.30
+0  (+0%)
ZYN002
Adult Epilepsy Patients with Refractory Focal Seizures
Phase 2
Phase 2 dosing commenced August 2016. Data are due July or August 2017.
AGN
$233.99
-0.57  (-0.24%)
Liletta
Prevention of pregnancy
PDUFA
sNDA accepted January 4, 2017. PDUFA estimate September 4, 2017.
MYL
$41.70
+0.03  (+0.07%)
MYL-1401O
Trastuzumab biosimilar
PDUFA
PDUFA date September 7, 2017.
FPRX
$37.04
-2.17  (-5.53%)
FP-1039
Mesothelioma cancer
Phase 1b
Phase 1b NSCLC halted, mesothelioma to continue. Data due at ESMO 8-12 September 2017. Exact date TBC.
AGN
$233.99
-0.57  (-0.24%)
ABP 215
Biosimilar candidate to Avastin (bevacizumab)
PDUFA
BLA filed November 15, 2016. PDUFA estimate September 15, 2017.
AMGN
$167.45
+0.6  (+0.36%)
ABP 215
Biosimilar candidate to Avastin (bevacizumab)
PDUFA
BLA filed November 15, 2016. PDUFA estimate September 15, 2017.
NEOS
$6.65
-0.56  (-7.64%)
NT-0201
Attention deficit hyperactivity disorder (ADHD)
PDUFA
NDA submission announced November 15, 2016. PDUFA estimate November 15, 2017.
GSK
$39.31
0  (0%)
FF/UMEC/VI
Chronic obstructive pulmonary disease (COPD)
PDUFA
Filing announced Novermber 21, 2016. PDUFA estimate September 21, 2017.
INVA
$12.86
+0  (+0%)
FF/UMEC/VI
Chronic obstructive pulmonary disease (COPD)
PDUFA
Filing announced November 21, 2016. PDUFA estimate September 21, 2017.
JNJ
$114.93
0  (0%)
Sirukumab
Rheumatoid arthritis
PDUFA
BLA filing announced September 23, 2016. PDUFA estimate September 23, 2017.
GSK
$39.31
0  (0%)
Sirukumab
Rheumatoid arthritis
PDUFA
BLA filing announced September 23, 2016. PDUFA estimate September 23, 2017.
IPCI
$2.27
-0.08  (-3.4%)
Rexista
Pain relief
PDUFA
PDUFA date September 25, 2017.
ABIO
$2.45
-0.05  (-2%)
Gencaro - GENETIC-AF trial
Chronic Heart Failure
Phase 2b
Phase 2b interim analysis due 3Q 2017.
ALDX
$5.00
+0.05  (+1.01%)
NS2
Allergic conjunctivitis
Phase 2b
Phase 2b enrollment initiation announced February 7, 2017. Data due 3Q 2017.
AMRN
$3.18
+0.01  (+0.32%)
Vascepa REDUCE-IT outcomes trial
High Triglycerides With Mixed Dyslipidemia
Interim analysis announced September 12, 2016 - trial to proceed.Second interim analysis due late 3Q 2017. Final data due 2018.
APRI
$2.26
+0.04  (+1.8%)
Vitaros
Erectile dysfunction
NDA Filing
NDA resubmission planned for 3Q 2017.
ARDX
$14.10
+0.8  (+6.02%)
RDX7675
Hyperkalemia
Onset of action trial data due 3Q 2017.
AST
$3.15
-0.25  (-7.35%)
AST-OPC1 SCiSTAR
Cervical spinal cord injury
Phase 1/2
Phase 1/2 six and nine-month data released January 24, 2017 from AIS-A 10 million-cell cohort. 12-month efficacy and safety data for this cohort, as well as 6-month efficacy and safety data for the currently-enrolling AIS-A 20 million cell and AIS-B 10 million cell cohorts, due 3Q 2017.
AXON
$14.23
-0.08  (-0.57%)
Intepirdine - MINDSET
Alzheimer's disease
Phase 3
Phase 3 data are due 3Q 2017.
AXSM
$3.55
-0.05  (-1.39%)
AXS-02 COAST-1
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3
Phase 3 commenced March 2016. Interim analysis due 3Q 2017.
BTX
$3.15
-0.1  (-3.08%)
AST-OPC1 - SCiStar
Cervical spinal cord injury
Phase 1/2
Phase 1/2 six and nine-month data released January 24, 2017 from AIS-A 10 million-cell cohort. 12-month efficacy and safety data for this cohort, as well as 6-month efficacy and safety data for the currently-enrolling AIS-A 20 million cell and AIS-B 10 million cell cohorts, due 3Q 2017.
CRBP
$9.25
-1.11  (-10.63%)
Anabasum (Resunab)
Dermatomyositis
Phase 2
Phase 2 data due 3Q 2017.
CUR
$5.35
-0.36  (-6.3%)
NSI-189
Major depressive disorder
Phase 2
Phase 2 data are due 3Q 2017.
CYTX
$1.64
-0.01  (-0.61%)
ECCS-50
Scleroderma
Phase 3
Pivotal trial initiated August 2015. Enrolment completed June 2016. Data are due 3Q 2017.
EARS
$0.90
-0.03  (-3.65%)
AM-111 HEALOS
Acute inner ear hearing loss
Phase 3
Phase 3 HEALOS data due 3Q 2017.
FGEN
$23.15
-1.95  (-7.77%)
Pamrevlumab (FG-3019)
Idiopathic pulmonary fibrosis
Phase 2
Phase 2 data due 3Q 2017.
GEMP
$11.66
+1.26  (+12.12%)
Gemcabene - ROYAL-1
Heterozygous Familial Hypercholesterolemia (HeFH)
Phase 2b
Phase 2b data due 3Q 2017.
GILD
$71.93
0  (0%)
GS-0976
Nonalcoholic steatohepatitis (NASH)
Phase 2
Phase 2 data due 3Q 2017.
GTXI
$4.92
-0.12  (-2.38%)
Enobosarm
Postmenopausal women with stress urinary incontinence (SUI)
Phase 2
Phase 2 initiated January 2016. Data are due 3Q 2017.
GTXI
$4.92
-0.12  (-2.38%)
Enobosarm
Breast cancer - metastatic or locally advanced, ER+/AR+ breast cancer
Phase 2
Phase 2 initial data released December, 8 2016. Top-line data due 3Q 2017.
MYOK
$13.90
-0.7  (-4.79%)
MYK-461 - PIONEER-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2
Phase 2 dosing initiated November 2016. Top-line data due 3Q 2017.
NBIX
$41.77
-2.12  (-4.83%)
Elagolix
Endometriosis
Phase 3
First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA Filing due 3Q 2017.
NBRV
$11.00
-0.15  (-1.35%)
Lefamulin - LEAP 1
Moderate to severe Community Acquired Bacterial Pneumonia (CABP)
Phase 3
Phase 3 topline data due by the end of 3Q 2017.
PRTA
$50.79
-3.55  (-6.53%)
PRX003
Psoriatic Arthritis
Phase 1b
Phase 1b data due 3Q 2017.
SMMT
$12.29
-0.35  (-2.73%)
Ezutromid
Duchenne muscular dystrophy
Phase 2
Phase 2 24-week data due 2Q or 3Q 2017.
VSAR
$19.70
-0.9  (-4.37%)
VRS-317 VELOCITY
Growth hormone deficiency, or GHD - pediatric
Phase 3
Phase 3 top-line data due 3Q 2017.
ZGNX
$10.35
-0.2  (-1.9%)
ZX008 - (Study 1)
Dravet syndrom
Phase 3
Phase 3 data due 3Q 2017.
FLXN
$19.54
-1.26  (-6.06%)
Zilretta - FX006
Osteoarthritis of the knee
PDUFA
PDUFA date October 6, 2017.
MYL
$41.70
+0.03  (+0.07%)
MYL-1401H
Neulasta biosimilar
PDUFA
PDUFA date October 9, 2017.
ACRX
$3.05
+0.1  (+3.39%)
ARX-04 (SAP303)
Moderate-to-severe acute pain following a surgical procedure
PDUFA
PDUFA date October 12, 2017. Advisory Committee meeting planned.
JNJ
$114.93
0  (0%)
STELARA (USTEKINUMAB)
Plaque psoriasis
PDUFA
sBLA filing announced December 15, 2016. PDUFA estimate October 15, 2017.
ATRS
$2.80
+0.15  (+5.66%)
VIBEX QuickShot
Testosterone deficiency
PDUFA
PDUFA date October 20, 2017.
JNJ
$114.93
0  (0%)
SIMPONI ARIA
Psoriatic arthritis (PsA)
PDUFA
sBLA filing announced December 21, 2016. PDUFA date estimate October 21, 2017.
JNJ
$114.93
0  (0%)
SIMPONI ARIA
Ankylosing Spondylitis
PDUFA
sBLA filing announced December 21, 2016. PDUFA date estimate October 21, 2017.
ALXN
$120.08
+1.38  (+1.15%)
Eculizumab
Refractory generalized myasthenia gravis (gMG)
PDUFA
(sBLA) PDUFA date October 23, 2017.
GSK
$39.31
0  (0%)
Shingrix
Shingles
PDUFA
BLA filing announced October 24, 2016. PDUFA estimate October 24, 2017.
PTCT
$8.37
-0.53  (-5.96%)
Translarna
Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)
PDUFA
Received a Refusal to File letter for their NDA Filing - February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest. New PDUFA date October 24, 2017.
EGRX
$77.43
-5.93  (-7.11%)
Ready-to-dilute (RTD) Pemetrexed Injection
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
PDUFA
PDUFA date October 30, 2017.
SYRS
$14.64
-1.39  (-8.67%)
SY-1425
Relapsed or refractory Acute myeloid leukemia (AML) and relapsed high-risk Myelodysplastic Syndrome (MDS) - cancer
Phase 2
Phase 2 initiated September 2016. Preliminary data due fall of 2017.
KERX
$5.68
-0.61  (-9.7%)
Auryxia
Iron deficiency anemia in non-dialysis dependent CKD patients
PDUFA
(sNDA) PDUFA date November 6, 2017.
JNJ
$114.93
0  (0%)
Guselkumab
Plaque psoriasis
PDUFA
BLA submission announced November 17, 2016. PDUFA date estimate November 17, 2017.
CLDX
$3.24
+0.07  (+2.21%)
Glembatumumab vedotin, varlilumab, Opdivo or Keytruda
Cancer - melanoma
Phase 2
Phase 2 continues to enroll. Glembatumumab vedotin and varlilumab arm data due fall of 2017.
NVO
$36.19
0  (0%)
Semaglutide
Type 2 diabetes
PDUFA
NDA filed December 5, 2016. PDUFA estimate December 5, 2017.
BLUE
$86.30
+2.25  (+2.68%)
LentiGlobin - HGB-206
Sickle disease
Phase 1/2
Update at ASH 2016. Further data due at ASH 2017. Exact date TBC.
ABBV
$61.79
0  (0%)
Imbruvica - PHOENIX
First-line Diffuse large B-cell lymphoma (DLBCL)
Phase 3
Phase 3 interim data possibly due 2H 2017.
ABBV
$61.79
0  (0%)
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3
Phase 3 data due 2017.
ABBV
$61.79
0  (0%)
Risankizumab
Psoriasis
Phase 3
Phase 3 data due by the end of 2017.
ABBV
$61.79
0  (0%)
Elagolix
Uterine Fibroids
Phase 3
Phase 3 initiated by partner Abbvie in January 2016. Data due 4Q 2017.
ABBV
$61.79
0  (0%)
ABT-494
Atopic Dermatitis
Phase 2b
Phase 2b data due 2017.
ABUS
$3.15
-0.05  (-1.56%)
ARB-1467
Hepatitis B (HBV)
Phase 2
Phase 2 Cohort 4 data due 4Q 2017.
ADXS
$7.70
-0.12  (-1.53%)
Axalimogene filolisbac + durvalumab
Recurrent or refractory HPV-associated cervical cancer and head & neck cancer
Phase 1/2
Phase 1/2 updated data due 2H 2017.
ADXS
$7.70
-0.12  (-1.53%)
Axalimogene filolisbac
Anal cancer (FAWCETT)
Phase 2
Phase 2 initiated June 2016. Preliminary update due 2H 2017.
AFMD
$2.35
-0.1  (-4.08%)
AFM13
Hodgkin Lymphoma - Cancer
Phase 2
Phase 2a trial to be initiated 1Q 2017 with an update due 2H 2017.
AGIO
$52.92
-0.23  (-0.43%)
AG-120
IDH1m Relapsed/Refractory AML - cancer
NDA Filing
NDA filing due by end of 2017.
AGIO
$52.92
-0.23  (-0.43%)
AG-348
Pyruvate kinase deficiency
Phase 2
Phase 2 first data released at EHA meeting June 2016. Updated data due 2H 2017. Pivotal trial design update due 3Q 2017.
AGN
$233.99
-0.57  (-0.24%)
Cortisol Analog
Dry Eye disease
Phase 3
Phase 3 trial to be initiated 2H 2017.
AIMT
$22.32
+0.34  (+1.55%)
AR101
Peanut Allergy
Phase 3
Phase 3 initiated January 2016. Enrollment completion announced November 28, 2016. Top-line data due 4Q 2017.
AKAO
$20.29
+0.25  (+1.25%)
Plazomicin - CARE
Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE)
NDA Filing
Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
ALKS
$59.43
+2.06  (+3.61%)
ALKS 3831 - ENLIGHTEN-1 and ENLIGHTEN-2
Schizophrenia
Phase 3
Pivotal trials initiated December 2015 and February 2016. Four week efficacy data due YE 2017. Six month weight data mid-2018.
ALNY
$53.25
-0.96  (-1.77%)
Fitusiran (ATLAS)
Hemophilia
Phase 3
Phase 3 program to be initiated 2Q 2017, with initial data due mid-late 2017
ALXN
$120.08
+1.38  (+1.15%)
Eculizumab
Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 3
Phase 3 data due 2017.
ANAB
$27.03
-0.49  (-1.78%)
ANB020
Moderate-to-severe adult atopic dermatitis
Phase 2
Phase 2a trial initiated 1Q 2017 with data due 2H 2017.
ANAB
$27.03
-0.49  (-1.78%)
ANB020
Severe adult peanut allergy
Phase 2a
Phase 2a trial initiated 1Q 2017 with data due 2H 2017.
ARNA
$1.43
-0.01  (-0.69%)
Etrasimod
Ulcerative colitis
Phase 2
Phase 2 data due by the end of 2017.
AXON
$14.23
-0.08  (-0.57%)
Nelotanserin
DLB patients experiencing REM Behavior Disorder (RBD)
Phase 2
Phase 2 data due 2H 2017.
AXON
$14.23
-0.08  (-0.57%)
Intepirdine - HEADWAY-DLB
Dementia with Lewy bodies (DLB)
Phase 2b
Phase 2b data due 4Q 2017
AXSM
$3.55
-0.05  (-1.39%)
AXS-02 CREATE-1
Complex regional pain syndrome (CRPS)
Phase 3
Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.
AZN
$28.53
0  (0%)
Tagrisso
First-line lung cancer
Phase 3
Phase 3 data due 2H 2017.
AZN
$28.53
0  (0%)
Moxetumomab
Cancer - leukaemia
Phase 3
Phase 3 data due 2H 2017.
AZN
$28.53
0  (0%)
Lynparza
First-line ovarian cancer
Phase 3
Phase 3 data due 2H 2017.
AZN
$28.53
0  (0%)
Durvalumab +/- tremelimumab (KESTREL)
Head & neck cancer
Phase 3
Phase 3 data due 2H 2017.
AZN
$28.53
0  (0%)
Durvalumab (PACIFIC)
Lung cancer
Phase 3
Phase 3 data due 2H 2017.
BIIB
$277.87
+2.08  (+0.75%)
BAN2401 (Aβ mAb)
Alzheimer’s disease
Phase 2
Phase 2 data potentially due late 2017 or early 2018.
BIIB
$277.87
+2.08  (+0.75%)
BG00011 (STX-100)
Idiopathic pulmonary fibrosis (IPF)
Phase 2
Phase 2 to be completed 2017.
BLPH
$1.32
-0.09  (-6.38%)
INOpulse delivery device
Pulmonary Arterial Hypertension (PAH)
Phase 3
Phase 3 commenced enrollment June 2016. Interim analysis due 4Q 2017 with top-line data due mid-2018.
BLRX
$1.12
+0.03  (+3.24%)
BL-8040 in combination with KEYTRUDA - COMBAT trial
Pancreatic cancer
Phase 2
Phase 2 initiated September 2016. Partial data due 2H 2017. Full data due 2H 2018.
BLRX
$1.12
+0.03  (+3.24%)
BL-8040
Mobilization and collection of bone marrow stem cells
Phase 2
Phase 2 trial initiated March 2016. Partial data released March 20, 2017 with topline results by the end of 2017 with Phase 2/3 trial to be initiated 2H 2017.
BMY
$56.47
0  (0%)
CM-459 – Opdivo
First-line Hepatocellular carcinoma (HCC) - cancer
Phase 3
Phase 3 data due 2H 2017.
BMY
$56.47
0  (0%)
CM-214 – Opdivo + Yervoy
First-line Renal cell carcinoma (RCC)
Phase 3
Phase 3 data due 2H 2017.
CALA
$10.55
-1.8  (-14.57%)
CB-839 + nivolumab
Renal cell carcinoma, malignant melanoma and non-small cell lung cancer
Phase 1/2
Phase 1/2 enrolment commenced August 2016. Initial data due 2H 2017.
CDTX
$7.05
+0.05  (+0.71%)
CD101 IV - STRIVE
Candidemia
Phase 2
Phase 2 initiated June 2016. Data due 4Q 2017.
CELG
$123.37
-0.45  (-0.36%)
REVLIMID - RELEVANCE
Newly Diagnosed Follicular Lymphoma
Phase 3
Phase 3 data due 2017.
CELG
$123.37
-0.45  (-0.36%)
REVLIMID - AUGMENT NHL-007
Relapsed or Refractory Follicular Lymphoma
Phase 3
Phase 3 enrolling. Data due 2017.
CELG
$123.37
-0.45  (-0.36%)
ABRAXANE - PANC-003 apact
Adjuvant Therapy in Surgically Resected Pancreatic Cancer
Phase 3
Phase 3 data due 2017.
CELG
$123.37
-0.45  (-0.36%)
ABRAXANE - NSCL-003 abound.70+
Elderly Non-small cell lung cancer (NSCLC)
Phase 3
Phase 3 data due 2017.
CELG
$123.37
-0.45  (-0.36%)
GED-0301
Ulcerative Colitis
Phase 2
Phase 2 data due 2017.
CELG
$123.37
-0.45  (-0.36%)
CC-486 with fulvestrant
ER+, HER2 breast cancer
Phase 2
Phase 2 data due 2017.
CELG
$123.37
-0.45  (-0.36%)
Durvalumab - FUSION
Relapsed and/or refractory multiple myeloma (RRMM), myelodysplastic syndromes and AML
Phase 1/2
Phase 1/2 data due 2017.
CEMP
$4.05
+0  (+0%)
Taksta - Fusidic acid
Refractory infections in bones and joints
Phase 2/3
Phase 2/3 data due by the end of 2017.
CERU
$1.12
-0.1  (-8.2%)
CRLX301
Solid tumours - cancer
Phase 2a
Phase 2a portion of Phase 1/2a trial commenced dosing June 2016. Initial data due in 2017.
CERU
$1.12
-0.1  (-8.2%)
CRLX101, in combination with LYNPARZA
Solid tumors - cancer
Phase 1/2
Phase 1/2 trial commenced dosing May 2016. Top-line data due 2017.
CERU
$1.12
-0.1  (-8.2%)
CRLX101 and paclitaxel
Platinum-resistant ovarian cancer
Phase 2
Further data due in 2017.
CLCD
$46.53
+0  (+0%)
Lasmiditan - SPARTAN
Migraine
Phase 3
Phase 3 data due 2H 2017. To be acquired by LLY.
CLRB
$2.38
+0  (+0%)
CLR 131
Various lymphoma
Phase 2
Phase 2 trial to be initiated 1Q 2017. Initial data due 2H 2017.
CLSD
$7.00
+0.09  (+1.3%)
Suprachoroidal CLS-TA
Diabetic macular edema (DME)
Phase 1/2
Phase 1/2 enrollment commenced November 2016. Preliminary data due 2H 2017.
CNCE
$17.00
-0.5  (-2.86%)
CTP-543
Alopecia areata
Phase 2a
Phase 2 trial to be initiated 1Q 2017 with top-line data due by the end of 2017.
CNCE
$17.00
-0.5  (-2.86%)
CTP-656
Cystic fibrosis
Phase 2
Phase 2 trial initiation announced December 21, 2016. Data due by end of 2017.
CORT
$10.02
-0.37  (-3.56%)
CORT125134
Cushing’s syndrome
Phase 2
Phase 2 trial initiated 2Q 2016. Data due by the end of 2017.
CPRX
$1.70
+0.04  (+2.41%)
Firdapse
Congenital Myasthenic Syndromes (CMS)
Phase 3
Phase 3 data due 2H 2017.
CPRX
$1.70
+0.04  (+2.41%)
Firdapse
Lambert-Easton Myasthenic Syndrome (LEMS)
Phase 3
Refusal to file letter reported on February 17, 2016. Announced that enrollment had commenced in second Phase 3 trial on December 15, 2016, with data and NDA resubmission due in 2017.
CTIC
$4.18
-0.06  (-1.42%)
PIXUVRI
B-cell non-Hodgkin lymphoma
Top-line data from confirmatory trial required for full EMA approval due by end of 2017.
CYTK
$12.20
-0.3  (-2.4%)
Tirasemtiv - VITALITY
Amyotrophic lateral sclerosis (ALS)
Phase 3
Phase 3 data are due 4Q 2017.
CYTR
$0.41
-0.02  (-3.48%)
Aldoxorubicin with doxorubicin
Soft tissue sarcomas refractory cancer
Phase 3
Phase 3 PFS data released July 2016 showed no significant improvement in PFS. Second analysis released November 29, 2016 showed improvement in population with leiomyosarcoma and liposarcoma. Overall survival data and NDA filing due 2017.
DBVT
$34.95
-0.47  (-1.33%)
Viaskin Milk
Cow’s milk protein allergy (CMPA)
Phase 1/2
Phase 1/2 data due 2H 2017.
DBVT
$34.95
-0.47  (-1.33%)
Viaskin Peanut
Peanut allergy
Phase 3
Phase 3 completion of enrollment announced March 10, 2017. Data due 2H 2017.
DCTH
$0.08
-0.01  (-8.83%)
Melphalan Hepatic Delivery System (Melphalan HDS)
Hepatocellular carcinoma (HCC) - cancer
Phase 3
Phase 3 initiated February 2016. Ongoing as of November 2016. Interim safety analysis due 2H 2017.
DMTX
$1.75
-0.25  (-12.5%)
DTX101
Ornithine Transcarbamylase (OTC) Deficiency
Phase 1/2
Phase 1/2 trial initiated December 2016. Initial data due 2H 2017.
DRRX
$0.91
-0.02  (-1.25%)
POSIMIR - PERSIST 3
Post-operative pain relief
Phase 3
CRL Feb 12 2014. Phase 3 commenced November 2015 in response to CRL. Enrollment originally expected to take one year but the company announced amendments to the trial on April 7, 2016, which will result in time added to complete the trial. Part 2 of the Phase 3 trial is expected to complete enrollment around 3Q 2017 with top-line data by the end of 2017.
EGLT
$4.62
-0.15  (-3.14%)
Egalet-002
Moderate to severe chronic pain
Phase 3
Phase 3 to be completed 4Q 2017. NDA planned for 2018.
ESPR
$39.05
-2.17  (-5.26%)
Bempedoic Acid/ Ezetimibe/ Atorvastatin (1002-038)
Hypercholesterolemia
Phase 2
Phase 2 initiation announced March 7, 2017. Data due 4Q 2017.
EXEL
$20.44
-1.6  (-7.26%)
XL184 cabozantinib (CELESTIAL)
Advanced hepatocellular cancer (HCC)
Phase 3
Phase 3 initiated Sept 2013. Data due 2017.
EYEG
$2.36
-0.08  (-3.44%)
EGP-437
Non-infectious anterior uveitis
Phase 3
Phase 3 enrollment to be completed 3Q 2017. Top-line data due 4Q 2017
FBIO
$3.43
-0.33  (-8.78%)
Triplex vaccine
Cytomegalovirus (CMV)
Phase 2
Phase 2 data due 2H 2017.
FLKS
$4.08
-0.1  (-2.39%)
FLX-787
Multiple Sclerosis
Phase 2
Phase 2 data due by the end of 2017.
FPRX
$37.04
-2.17  (-5.53%)
FPA008
Pigmented Villonodular Synovitis (PVNS)
Phase 1/2
Phase 2 dose expansion phase initiated May 2016. Enrollment to be completed 2H 2017. Data due 2017.
GALT
$2.01
-0.1  (-4.74%)
GR-MD-02
Non-alcoholic steatohepatitis (NASH) with cirrhosis
Phase 2b
Phase 2b top-line data due December 2017.
GBT
$36.30
-1.05  (-2.81%)
GBT440
Sickle cell disease in adolescents
Phase 1/2
Phase 2a initiated June 2016. Data due 2017
GEMP
$11.66
+1.26  (+12.12%)
Gemcabene - INDIGO-1
Severe Hypertriglyceridemia (SHTG)
Phase 2b
Phase 2b data due 4Q 2017.
GILD
$71.93
0  (0%)
GS-9674
Nonalcoholic steatohepatitis (NASH)
Phase 2
Phase 2 data due 4Q 2017.
GNCA
$5.62
-0.2  (-3.44%)
GEN-003
Genital herpes
Phase 2b
Phase 2b data released January 6, 2017. 12-month data due 2H 2017. Phase 3 to commence 4Q 2017.
GNMX
$1.75
-3.97  (-69.41%)
AEVI-002 (Anti-LIGHT mAb)
Pediatric onset Crohn's disease
Phase 1/2
Phase 1/2 data due 2H 2017.
GSK
$39.31
0  (0%)
Nucala
Chronic obstructive pulmonary disease (COPD)
Phase 3
Phase 3 data due 2017.
GSK
$39.31
0  (0%)
GSK 166
Rheumatoid arthritis
Phase 2b
Phase 2b data due 2H 2017.
GSK
$39.31
0  (0%)
GSK 165
Osteoarthritis
Phase 2
Phase 2 data due 2H 2017.
GWPH
$119.06
-3.41  (-2.78%)
GWP42006 (CBDV)
Epilepsy
Phase 2
Phase 2 initiated May 2015. Data due 2H 2017.
ICPT
$116.01
-7.55  (-6.11%)
Obeticholic acid (OCA) AESOP
Primary Sclerosing Cholangitis (PSC)
Phase 2
Phase 2 data due 2017.
INSM
$15.36
-0.93  (-5.71%)
ARIKAYCE
Non-tuberculous Mycobacterial Lung Disease
Phase 3
Phase 3 data due 2H 2017.
IRWD
$16.95
-0.66  (-3.75%)
IW-1973
Type 2 diabetes
Phase 2
Phase 2a data due in 2017.
KDMN
$3.93
-0.08  (-2%)
KD025
Chronic graft-versus-host disease (cGVHD)
Phase 2
Phase 2 initiated September 2016. Data due 4Q 2017.
KDMN
$3.93
-0.08  (-2%)
KD025
Idiopathic pulmonary fibrosis (IPF)
Phase 2
Phase 2 data due 4Q 2017.
KDMN
$3.93
-0.08  (-2%)
KD025
Moderate to severe chronic plaque psoriasis
Phase 2
Phase 2 first patient dosed September 2016. Data due 4Q 2017.
KITE
$76.67
-8.27  (-9.74%)
KTE-C19 (ZUMA-6)
Refractory diffuse large B-cell lymphoma (DLBCL)
Phase 1/2
Phase 1/2 initiated October 2016. Phase 1 data due 2017.
KURA
$8.45
-0.3  (-3.43%)
Tipifarnib
HRAS mutant solid tumors - cancer
Phase 2
Phase 2 ongoing data released March 6, 2017 - further data due 2H 2017.
KURA
$8.45
-0.3  (-3.43%)
Tipifarnib
Lower risk myelodysplastic syndromes (MDS) - cancer
Phase 2
Phase 2 dosing commenced June 2016. Top-line data due 2H 2017.
LBIO
$7.25
-0.45  (-5.84%)
LN-144
Refractory metastatic melanoma
Phase 2
Phase 2 continues to enrol as of March 2016. Initial data to be presented in 2017.
LLY
$76.76
0  (0%)
Lasmiditan - SPARTAN
Migraine
Phase 3
Phase 3 data due 2H 2017. LLY buyout of CLCD due 1Q 2017.
LLY
$76.76
0  (0%)
Ramucirumab
Second-line bladder cancer
Phase 3
Phase 3 PFS data due 2017.
LLY
$76.76
0  (0%)
Flortaucipir F 18 (Tau imaging agent)
Alzheimer's disease
Phase 3
Phase 3 ongoing. Data due 2017.
LLY
$76.76
0  (0%)
Alimta + Keytruda
First-Line Non-Squamous Non-Small Cell Lung Cancer
Phase 3
Phase 3 data due late 2017.
LLY
$76.76
0  (0%)
Abemaciclib - MONARCH 3
HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)
Phase 3
Phase 3 data due late 2017.
LLY
$76.76
0  (0%)
Abemaciclib - JUNIPER
Thrid line KRAS mutation positive Non-small cell lung cancer (NSCLC)
Phase 3
Phase 3 ongoing. Data due 2017.
LOXO
$43.43
-2.67  (-5.79%)
LOXO-101
Solid tumors that harbor a TRK fusion.
Phase 2
Announced February 21, 2017 that trial enrollment has been completed with Phase 2 data due 2H 2017. NDA filing late 2017 or early 2018.
MATN
$0.64
+0.01  (+2.4%)
CA4P Fosbretabulin - FOCUS
Cancer - Platinum-Resistant Ovarian Cancer
Phase 2/3
Phase 2/3 trial commenced June 2016. Data due 2H 2017.
MBRX
$1.07
-0.1  (-8.56%)
Annamycin
Acute myeloid leukemia (AML) - cancer
Phase 2
Phase 2 data due 2H 2017.
MCRB
$11.10
-0.89  (-7.42%)
SER-262
Primary Clostridium Difficile infection (CDI)
Phase 1b
Phase 1b initiated July 2016. Data due 2017
MCRB
$11.10
-0.89  (-7.42%)
SER-287
Mild-to-Moderate Ulcerative Colitis
Phase 1b
Phase 1b initiated December 2015. Enrolment ongoing as of May 2016. Data due 2017.
MNOV
$5.81
-0.16  (-2.68%)
MN-166
Progressive multiple sclerosis (progressive MS)
Phase 2b
Phase 2b final data due 2H 2017.
MRK
$61.37
0  (0%)
(MK-3475-189/KEYNOTE-189)
First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3
Phase 3 data due 4Q 2017.
MRK
$61.37
0  (0%)
Ertugliflozin
Type 2 diabetes
PDUFA
PDUFA date set for December 2017 - exact date not provided. December 31 entered as latest possible date for calendar entry purposes only.
MRNS
$1.45
-0.08  (-4.62%)
Ganaxolone
Refractory status epilepticus (RSE)
Phase 2
Phase 2 trial to commence in 1H 2017 with data due in 2H 2017.
MRNS
$1.45
-0.08  (-4.62%)
Ganaxolone
Postpartum depression
Phase 2
Phase 2 trial to commence in 1H 2017 with data due in 2H 2017.
MRTX
$5.20
-0.25  (-4.59%)
Glesatinib (MGCD265)
Non-small cell lung cancer (NSCLC) patients with driver alterations in MET
Phase 2
Phase 2 initiated December 2015. Enrollment ongoing - update due 2H 2017.
MRUS
$26.06
-2.44  (-8.56%)
MCLA-128
Solid tumors
Phase 1/2
Phase 1/2 top-line data due 2H 2017.
MRUS
$26.06
-2.44  (-8.56%)
MCLA-117
Acute myeloid leukemia (AML)
Phase 1/2
Phase 1/2 interim data due 2H 2017.
MSTX
$0.10
+0  (+0.68%)
AIR001
Heart failure with preserved ejection fraction (HFpEF)
Phase 2
Phase 2 data due 4Q 2017.
NBIX
$41.77
-2.12  (-4.83%)
Elagolix
Uterine Fibroids
Phase 3
Phase 3 initiated by partner Abbvie in January 2016. Data due 4Q 2017.
NLNK
$20.65
-1.75  (-7.81%)
Indoximod + temozolomide
Glioblastoma multiforme cancer
Phase 2
Phase 2 data due 2H 2017.
NVO
$36.19
0  (0%)
Semaglutide (NN9536)
Obesity
Phase 2
Phase 2 data due 2017.
NVS
$71.95
0  (0%)
LEE011: MONALEESA-3
Breast cancer - (post-menopausal)
Phase 3
Phase 3 data due 2H 2017.
OTIC
$12.25
-0.85  (-6.49%)
OTO-104 AVERTS-1 and AVERTS-2
Ménière's disease
Phase 3
Second Phase 3 trial initiated March 2016. Data from both Phase 3 trials due 2H 2017.
PFE
$31.96
0  (0%)
Talazoparib (EMBRACA)
BRCA-mutated breast cancer
Phase 3
Phase 3 data due 2017. Estimate 2H 2017 using clinicaltrials.gov data.
PFE
$31.96
0  (0%)
Ertugliflozin
Type 2 diabetes
Phase 3
PDUFA date set for December 2017 - exact date not provided. December 31 entered as latest possible date for calendar entry purposes only.
PLX
$1.10
-0.05  (-4.35%)
OPRX-106
Ulcerative Colitis
Phase 2
Phase 2 trial initiation announced November 30, 2016. Data due around the end of 2017.
PSTI
$1.20
-0.08  (-5.51%)
PLX-PAD (stem cells)
Intermittent claudication, or IC
Phase 2
Phase 2 put on clinical hold Jun 2013. Lifted Sept 2013. Enrollment completed May 2016. Data are due late 2017.
PULM
$3.88
+1.1  (+39.57%)
PUR0200
COPD
Phase 2
Phase 2 data due 4Q 2017.
RARE
$77.72
-7.35  (-8.64%)
Aceneuramic acid extended release (Ace-ER)
GNE Myopathy
Phase 3
Phase 3 data due 2H 2017.
REGN
$369.14
-1.84  (-0.5%)
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
Phase 3
Phase 3 data due 4Q 2017.
REGN
$369.14
-1.84  (-0.5%)
REGN2222
Respiratory syncytial virus (RSV)
Phase 3
Phase 3 data due 2H 2017.
REGN
$369.14
-1.84  (-0.5%)
Dupixent (dupilumab) - LIBERTY ASTHMA QUEST
Asthma
Phase 3
Phase 3 data due 4Q 2017.
REGN
$369.14
-1.84  (-0.5%)
Dupixent (dupilumab)
Eosinophilic esophagitis
Phase 2
Phase 2 data due 2H 2017.
RETA
$26.46
-0.87  (-3.18%)
Bardoxolone methyl - CARDINAL
Chronic Kidney Disease Caused by Alport Syndrome
Phase 2/3
Phase 2/3 trial initiation announced February 23, 2017. Data from Phase 2 part of trial due by the end of 2017.
RETA
$26.46
-0.87  (-3.18%)
Omaveloxolone - MOTOR
Mitochondrial myopathies (MM)
Phase 2
Phase 2 initial data due 2H 2017.
RETA
$26.46
-0.87  (-3.18%)
Omaveloxolone - REVEAL
Metastatic melanoma
Phase 1/2
Phase 1b portion of trial due 2H 2017.
RGLS
$1.20
+0.03  (+2.13%)
RG-012
Renal biopsy study in Alport patients
Phase 1/2
Phase 1/2 data due 4Q 2017.
RGNX
$22.10
-2  (-8.31%)
RGX-501
Homozygous familial hypercholesterolemia (HoFH)
Phase 1/2
Phase 1/2 dosing initiated - March 8, 2017. Interim data due by the end of 2017.
RIGL
$2.72
-0.24  (-8.11%)
Fostamatinib
Autoimmune hemolytic anemia (AIHA)
Phase 2
Phase 2 data from first of two stages due in 2017.
RNN
$0.42
-0.05  (-8.98%)
Supinoxin
Triple negative breast cancer
Phase 2a
Phase 2a initiation of dosing announced February 23, 2017, initial data due 2H 2017.
RNN
$0.42
-0.05  (-8.98%)
RX-3117
Relapsed and refractory pancreatic cancer
Phase 2
Updated Phase 2a data presented at ASCO GI January 20, 2017. Final data due 2H 2017.
RTRX
$17.43
-0.84  (-4.6%)
Liquid ursodeoxycholic acid (L-UDCA)
Primary biliary cholangitis (PBC)
NDA Filing
NDA filing due 2017
RVNC
$19.55
-0.95  (-4.63%)
RT002
Plantar fasciitis
Phase 2
Phase 2 data due 2H 2017.
RVNC
$19.55
-0.95  (-4.63%)
RT002 - SAKURA
Moderate to severe glabellar (frown) lines
Phase 3
Phase 3 completion of enrollment announced March 8, 2017. Data due 4Q 2017.
RXDX
$8.35
-0.56  (-6.18%)
RXDX-105
Solid tumors - cancer
Phase 1b
Phase 1b data update 2H 2017.
RXII
$0.74
-0.01  (-0.41%)
RXI-109-1501
Retinal scarring
Phase 1/2
Phase 2 enrollment to be completed early 2017. Safety data readout due 2H 2017.
SAGE
$63.77
-4.63  (-6.77%)
SAGE-217
Postpartum depression (PPD)
Phase 2
Phase 2 initiation 4Q 2016. Data due 2H 2017.
SAGE
$63.77
-4.63  (-6.77%)
SAGE-547
Postpartum Depression
Phase 2
Phase 2 trial met primary endpoint July 2016. 202B and 202C trial data due 2H 2017 with NDA filing due in 2018.
SAGE
$63.77
-4.63  (-6.77%)
SAGE-217
Essential tremor
Phase 2
Announced that screening has opened for Phase 2a trial - December 13, 2016. Data due 2H 2017.
SCYX
$2.80
-0.02  (-0.71%)
SCY-078
Invasive candidiasis
Phase 2
Phase 2 trial to be initiated 1Q 2017 with data due 4Q 2017.
SGEN
$61.95
-6.07  (-8.92%)
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
Phase 3
Phase 3 data due in 2017.
SNDX
$13.23
-1.04  (-7.29%)
E2112
HR+, HER2- breast cancer
Phase 3
Phase 3 PFS data due by the end of 2017.
SNGX
$2.35
-0.19  (-7.48%)
SGX301 (synthetic hypericin)
Cutaneous T-Cell Lymphoma (CTCL) cancer
Phase 3
Phase 3 data due 2H 2017.
SNY
$41.04
0  (0%)
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
Phase 3
Phase 3 data due 4Q 2017.
SNY
$41.04
0  (0%)
Dupixent (dupilumab) - LIBERTY ASTHMA QUEST
Asthma
Phase 3
Phase 3 data due 4Q 2017.
SNY
$41.04
0  (0%)
Dupixent (dupilumab)
Eosinophilic esophagitis
Phase 2
Phase 2 data due 2H 2017.
SPHS
$2.54
-0.05  (-1.93%)
Topsalysin (PRX302)
Localized low to intermediate risk prostate cancer
Phase 2
Phase 2b initial data due end of 2017.
SPPI
$6.42
-0.09  (-1.38%)
Poziotinib
Breast cancer
Phase 2
Phase 2 initiated March 2016. Data due by the end of 2017.
STML
$8.70
-0.9  (-9.39%)
SL-401
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) cancer
Phase 2
Phase 2 enrollment to be completed 1Q 2017. Data due 2H 2017.
TBPH
$31.86
-1.87  (-5.54%)
TD-9855
nOH
Phase 2a
Phase 2a data due 2017.
TCON
$4.30
-0.25  (-5.49%)
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2
Phase 2 initiated Dec 2014. Phase 2 data top-line PFS data due 2H 2017.
TCON
$4.30
-0.25  (-5.49%)
TRC105
Gestational Trophoblastic Neoplasia cancer
Phase 2
Phase 2 planned for 2016. Data due 4Q 2017.
TCON
$4.30
-0.25  (-5.49%)
TRC102
Mesothelioma cancer
Phase 2
Phase 2 initiated October 2015. Data are due in 2017.
TGTX
$11.75
-1.5  (-11.32%)
TG-1101
Multiple Sclerosis
Phase 2
Phase 2 completion of enrollment announced January 11, 2017. Data to be presented at a conference in 2017. Phase 3 to be initiated 1H 2017.
TSRO
$155.78
+6.11  (+4.08%)
Niraparib - BRAVO
Cancer - breast
Phase 3
Phase 3 data due 2H 2017.
TSRO
$155.78
+6.11  (+4.08%)
Niraparib - (QUADRA trial)
Cancer - ovarian
Phase 2
Phase 2 data due 2H 2017.
TTPH
$7.95
-0.42  (-5.02%)
Eravacycline (TP-434)
cIAI (complicated intra-abdominal infections)
Phase 3
Announced Dec 17, 2014 that their Phase 3 trial met endpoints. Additional Phase 3 trial (IGNITE-4) data due 4Q 2017.
VKTX
$1.24
-0.05  (-3.88%)
VK2809
Hypercholesterolemia
Phase 2
Phase 2 data due late 2017.
VNDA
$13.90
-0.25  (-1.77%)
Tradipitant
Gastroparesis
Phase 2
Phase 2 enrolment to commence 4Q 2016 with data due 2H 2017
VNDA
$13.90
-0.25  (-1.77%)
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 2
Phase 2 data due in 2H 2017.
VRTX
$89.50
-1.81  (-1.98%)
VX-440 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Phase 2
Phase 2 data due 2H 2017.
VRTX
$89.50
-1.81  (-1.98%)
VX-152 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Phase 2
Phase 2 data due 2H 2017
XLRN
$26.55
-1.49  (-5.31%)
ACE-083
Facioscapulohumeral muscular dystrophy
Phase 2
Phase 2 dosing initiation announced December 22, 2016. Open label initial data due late 2017, with randomized part of trial to be initiated in 2018.
XLRN
$26.55
-1.49  (-5.31%)
Dalantercept - DART Study
Renal Cell Carcinoma (RCC) - cancer
Phase 2
Phase 2 preliminary data due 2H 2017.
XNCR
$23.24
-1.15  (-4.72%)
XmAb5871
IgG4-Related Disease (IgG4-RD)
Phase 2
Phase 2 top-line data due in 2017.
ZGNX
$10.35
-0.2  (-1.9%)
ZX008
Lennox-Gastaut syndrome
Phase 3
Phase 3 trial to be initiated 2H 2017.
ACOR
$25.55
-0.05  (-0.2%)
Tozadenant
Parkinson’s disease (PD)
Phase 3
Phase 3 data due 1Q 2018.
AMAG
$21.75
+0.35  (+1.64%)
Rekynda
Hypoactive sexual desire disorder (HSDD)
NDA Filing
NDA filing due early 2018.
ANTH
$0.41
-0.02  (-2.86%)
Sollpura - RESULT
Exocrine pancreatic insufficiency
Phase 3
Phase 3 data due end of 2017 or early 2018.
AXSM
$3.55
-0.05  (-1.39%)
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3
Phase 3 initiated March 2016. Top-line data due 1Q 2018.
AZN
$28.53
0  (0%)
Brilinta (THEMIS)
Type 2 Diabetes
Phase 3
Phase 3 data due 1Q 2018.
CLBS
$4.87
-0.29  (-5.62%)
CLBS03
Type 1 diabetes
Phase 2
Phase 2 enrollment of first cohort completed September 2016. Second cohort commenced enrollment October 2016. Interim analysis due late 2017 or early 2018.
CLSD
$7.00
+0.09  (+1.3%)
CLS-1001
Macular edema associated with non-infectious uveitis
Phase 3
Phase 3 data preliminary data due early 2018.
EARS
$0.90
-0.03  (-3.65%)
AM-101 - TACTT3
Acute inner ear tinnitus
Phase 3
Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018.
EIGR
$10.55
-0.7  (-6.22%)
Ubenimex - LIBERTY
Pulmonary arterial hypertension (PAH)
Phase 2
Phase 2 initiated July 2016. Enrollment to be completed 2Q 2017 with data due 1Q 2018.
FGEN
$23.15
-1.95  (-7.77%)
Pamrevlumab (FG-3019)
Pancreatic cancer
Phase 2
Phase 2 ongoing. Data due late 2017 or 1Q 2018.
KPTI
$10.14
-0.53  (-4.97%)
Selinexor - STORM
Quadruple Refractory Multiple Myeloma
Phase 2
Phase 2 positive top-line data released September 6, 2016. Updated data at ASH 2016. Top-line data from expansion cohort due early 2018.
PFE
$31.96
0  (0%)
Tanezumab
Chronic low back pain
Phase 3
Phase 3 ongoing. Estimate data due late 2017 or early 2018 using clinicaltrials.gov data.
PFE
$31.96
0  (0%)
Tanezumab
Osteoarthritis
Phase 3
Phase 3 ongoing. Estimate data late 2017 or early 2018 using clinicaltrials.gov data.
SBBP
$4.30
-0.35  (-7.53%)
COR-003 (levoketoconazole) - SONICS
Endogenous Cushing’s syndrome
Phase 3
Phase 3 top-line data due 1Q 2018.
SGMO
$4.05
-0.3  (-6.9%)
SB-318
MPS Type 1
Phase 1/2
Phase 1/2 trial to be initiated early 2017 with data due late 2017 or early 2018.
SGMO
$4.05
-0.3  (-6.9%)
SB-FIX
Hemophilia B
Phase 1/2
Phase 1/2 data due late 2017 or early 2018.
SGMO
$4.05
-0.3  (-6.9%)
SB-913
MPS Type 2
Phase 1/2
Phase 1/2 trial to be initiated early 2017 with data due late 2017 or early 2018.
TCON
$4.30
-0.25  (-5.49%)
TRC105 and Nexavar
Hepatocellular carcinoma (HCC) - cancer
Phase 2
Phase 2 dosing initiated May 2016 with data due early 2018.
VICL
$2.16
-0.04  (-1.82%)
ASP0113 Vaccine
Hematopoietic cell transplant recipients
Phase 3
Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q 2018.
VTVT
$5.93
-0.12  (-1.98%)
Azeliragon - STEADFAST
Mild Alzheimer’s disease
Phase 3
Phase 3 initiated 2Q 2015. Part A enrollment completed September 2016. Data from Part A due early 2018. Part B due late 2018.
ALDR
$20.85
+0.05  (+0.24%)
ALD403 - PROMISE 2
Frequent episodic migraine
Phase 3
Phase 3 PROMISE 2 initiation announced November 28, 2016. Data due 1H 2018.
ALKS
$59.43
+2.06  (+3.61%)
ALKS 8700
Multiple sclerosis (MS)
Phase 3
Phase 3 trial to be initiated 2017 with data and NDA filing due 2018. BPC estimate of data mid-2018.
AMGN
$167.45
+0.6  (+0.36%)
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
Phase 3
Phase 3 enrolling. Estimate data 1H 2018 using clinicaltrials.gov data.
ANAB
$27.03
-0.49  (-1.78%)
ANB020
Severe adult eosinophilic asthma
Phase 2a
Phase 2a trial to be initiated 1H 2017 with data due 1H 2018.
ATNM
$1.41
+0.01  (+0.71%)
Iomab-B
Hematopoietic Stem Cells Transplantation
Phase 3
Phase 3 initiated June 2016. Data due 1H 2018.
AZN
$28.53
0  (0%)
Durvalumab +/- tremelimumab (EAGLE)
Head & neck cancer
Phase 3
Phase 3 data due 1H 2018.
BMY
$56.47
0  (0%)
CM-651 – Opdivo + Yervoy
First-line Head and Neck Cancer
Phase 3
Phase 3 data due 1H 2018.
BMY
$56.47
0  (0%)
CM-451 – Opdivo + Yervoy
First-line Small cell lung cancer (SCLC)
Phase 3
Phase 3 data due 1H 2018.
BMY
$56.47
0  (0%)
CM-331– Opdivo
Second-line Small cell lung cancer (SCLC)
Phase 3
Phase 3 data due 1H 2018.
BMY
$56.47
0  (0%)
CM-227 – Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3
Phase 3 data due 1H 2018.
BMY
$56.47
0  (0%)
CM-078 – Opdivo
Second-line Non-small cell lung cancer (NSCLC)
Phase 3
Phase 3 data due 1H 2018.
BMY
$56.47
0  (0%)
CM-548 - Opdivo+SOC
First-line Glioblastoma (GBM) cancer
Phase 2
Phase 2 data due 1H 2018.
CNAT
$4.40
-0.02  (-0.45%)
Emricasan
Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)
Phase 2b
Phase 2b initiated May 2014. Topline data due 1H 2018.
DERM
$33.69
-1.76  (-4.96%)
Olumacostat glasaretil (DRM01)
Acne
Phase 3
Phase 3 trial initiation announced January 3, 2017. Data are due 1H 2018.
EBIO
$1.91
-0.03  (-1.55%)
Vicinium
Non-muscle invasive bladder cancer (NMIBC)
Phase 3
Phase 3 top-line data due 1H 2018.
EIGR
$10.55
-0.7  (-6.22%)
Ubenimex - ULTRA
Secondary lymphedema
Phase 2
Phase 2 dosing commenced July 2016. Enrollment to be completed 3Q 2017. Data due 2Q 2018.
ESPR
$39.05
-2.17  (-5.26%)
Bempedoic acid (ETC-1002-040)
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 3
Phase 3 long-term safety and tolerability trial initiated January 2016. Completion of enrollment announced January 25, 2017. Top-line results due 2Q 2018.
FBIO
$3.43
-0.33  (-8.78%)
CEVA101
Severe Traumatic Brain Injury
Phase 2
Phase 2 data in children due 1H 2018, in adults by 1H 2019.
FBIO
$3.43
-0.33  (-8.78%)
Pepvax vaccine
Cytomegalovirus (CMV)
Phase 2
Phase 2 data due 1H 2018.
FLKS
$4.08
-0.1  (-2.39%)
FLX-787
Amyotrophic lateral sclerosis (ALS)
Phase 2
Phase 2 initiated September 2016. Readout due 2017/18.
GLMD
$4.78
-0.23  (-4.59%)
Aramchol - ARREST
Non-Alcoholic Steatohepatitis (NASH)
Phase 2b
Phase 2b enrollment complettion announced January 9, 2017. Data due 2Q 2018.
IDRA
$2.09
-0.15  (-6.28%)
IMO-8400
Dermatomyositis
Phase 2
Phase 2 initiated November 2015. Enrollment to be completed by the end of 2017 with data due 1H 2018.
JNJ
$114.93
0  (0%)
Esketamine
Treatment resistant depression
Phase 3
Phase 3 ongoing. Data and regulatory filings likely due 2018.
KMPH
$4.10
-0.12  (-2.96%)
KP415
ADHD
Phase 2
Phase 1 trial completed December 2016. Efficacy trials to commence 2H 2017, with data 1H 2018.
MACK
$3.02
-0.19  (-5.92%)
MM-141
Cancer - front line pancreatic cancer
Phase 2
Phase 2 data due 1H 2018.
MDWD
$6.05
+0.05  (+0.83%)
NexoBrid
Severe burns
Phase 3
Phase 3 initiated mid April 2015. Data due 1H 2018.
NVS
$71.95
0  (0%)
LEE011: MONALEESA-7
Breast cancer - (pre-menopausal)
Phase 3
Phase 3 data 1H 2018.
OBSV
$11.32
+0.12  (+1.07%)
OBE2109 - EDELWEISS
Endometriosis
Phase 2b
Phase 2b data due 1H 2018.
OCUL
$9.17
-0.7  (-7.09%)
OTX-TP
Glaucoma and ocular hypertension
Phase 3
Phase 3 initiated October 2016. Data due 1H 2018.
PRTA
$50.79
-3.55  (-6.53%)
NEOD001 PRONTO
Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction
Phase 2b
Phase 2b data due 2Q 2018.
RETA
$26.46
-0.87  (-3.18%)
Bardoxolone methyl - CATALYST
Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH
Phase 3
Phase 3 commenced enrolment October 2016 with data due 1H 2018.
SGEN
$61.95
-6.07  (-8.92%)
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Phase 3
Phase 3 enrollment completed November 2016. Data are due 2017 or 2018.
TNXP
$3.71
-0.25  (-6.31%)
TNX-102 SL
Post-traumatic stress disorder (PTSD)
Phase 3
First of two Phase 3 trials to be initiated in military-related PTSD 1Q 2017. Interim analysis due 1H 2018 with top-line data due 2H 2018.
VICL
$2.16
-0.04  (-1.82%)
VCL-HB01
HSV-2 therapeutic vaccine
Phase 2
Phase 2 top-line data due 2Q 2018.
ESPR
$39.05
-2.17  (-5.26%)
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048
Hypercholesterolemia - statin intolerance
Phase 3
Phase 3 initiation of efficacy trials announced January 8, 2017. Data due mid 2018.
HSGX
$1.62
-0.11  (-6.35%)
NeoCart
Cartilage defects in the knee
Phase 3
Phase 3 top-line data due mid 2018.
RGLS
$1.20
+0.03  (+2.13%)
RG-012 - HERA
Alport Syndrome
Phase 2
Phase 2 interim data due mid-2018.
VTL
$4.25
-0.3  (-6.59%)
VTI-308
Alcohol-induced liver decompensation, or AILD
Phase 3
Phase 3 VTI-208 trial failed. New VTI-308 trial initiated May 2016. Data due mid 2018.
SBBP
$4.30
-0.35  (-7.53%)
COR-003 (levoketoconazole) - LOGICS
Endogenous Cushing’s syndrome
Phase 3
Phase 3 enrollment from second trial to begin mid-2017 with top-line data expected in 3Q 2018.
CNCE
$17.00
-0.5  (-2.86%)
AVP-786
Agitation in patients with Alzheimer's disease
Phase 3
Phase 3 initiated December 2015. Trial to be completed 3Q 2018
AGN
$233.99
-0.57  (-0.24%)
Brazikumab
Crohn's disease
Phase 2b
Phase 2b data due 2018.
AGN
$233.99
-0.57  (-0.24%)
Cariprazine
Major depressive disorder (MDD)
Phase 3
Phase 3 data due 2018.
AGN
$233.99
-0.57  (-0.24%)
ATOGEPANT
Prophylaxis (migraine)
Phase 2b
Phase 2b top-line data due 2018.
AGN
$233.99
-0.57  (-0.24%)
UBROGEPANT
Acute (migraine)
Phase 3
Phase 3 initiated July 2016. Data due 2018.
AGN
$233.99
-0.57  (-0.24%)
ABICIPAR
Age-related macular degeneration (AMD)
Phase 3
Phase 3 data due 2018.
ALDX
$5.00
+0.05  (+1.01%)
NS2
Noninfectious anterior uveitis
Phase 2
Phase 3 to begin 2Q 2017 with data due late 2018.
AMGN
$167.45
+0.6  (+0.36%)
ABP 710
REMICADE biosimilar - rheumatoid arthritis
Phase 3
Phase 3 enrolling. Estimate data end of 2018 using clinicaltrials.gov data.
AQXP
$15.09
-0.39  (-2.52%)
AQX-1125 LEADERSHIP
Bladder pain syndrome/interstitial cystitis (BPS/IC).
Phase 3
Phase 2 trial did not meet endpoints - June 2015 but positive secondary endpoint data - August 2015. Phase 3 trial commenced September 2016. Reported March 9, 2017 that enrollment has been slower than expected. Data now due 2018.
AZN
$28.53
0  (0%)
Selumetinib - ASTRA
Thyroid cancer
Phase 3
Phase 3 data due 2018.
AZN
$28.53
0  (0%)
Roxadustat - ANDES
Anaemia
Phase 3
Phase 3 data due 2018.
AZN
$28.53
0  (0%)
PT010
Chronic obstructive pulmonary disease (COPD)
Phase 3
Phase 3 data due 2018.
AZN
$28.53
0  (0%)
Durvalumab +/- tremelimumab (NEPTUNE)
Lung cancer
Phase 3
Phase 3 data due 2018.
AZN
$28.53
0  (0%)
Durvalumab +/- tremelimumab (DANUBE)
Bladder cancer
Phase 3
Phase 3 data due 2018.
AZN
$28.53
0  (0%)
Bydureon
Type 2 Diabetes
Phase 3
Phase 3 Cardiovascular Outcome trial data due 2018.
AZN
$28.53
0  (0%)
Anifrolumab
Lupus
Phase 3
Phase 3 data due 2018.
BLRX
$1.12
+0.03  (+3.24%)
BL-8040
Consolidation treatment for AML cancer patients
Phase 2b
Phase 2b initiated August 2015. Interim analysis due in 2018, with top-line results expected in 2019.
BMY
$56.47
0  (0%)
CM-602 – Opdivo + Elo + SOC
Myeloma
Phase 3
Phase 3 data due 2H 2018.
BMY
$56.47
0  (0%)
CM-238 – Opdivo (Adjuvant)
Melanoma
Phase 3
Phase 3 data due 2H 2018.
CELG
$123.37
-0.45  (-0.36%)
REVLIMID - ROBUST
First-line ABC Diffuse large B-cell lymphoma (DLBCL)
Phase 3
Phase 3 data due 2018.
CELG
$123.37
-0.45  (-0.36%)
POMALYST/IMNOVID - OPTIMISSM
Multiple Myeloma - refractory
Phase 3
Phase 3 trial to complete enrollment 1H 2017. Data due 2018.
CELG
$123.37
-0.45  (-0.36%)
Ozanimod - TRUE NORTH
Ulcerative Colitis
Phase 3
Phase 3 enrolling. Data due 2018.
CELG
$123.37
-0.45  (-0.36%)
OTEZLA - BCT-002 RELIEF
Behçet’s Disease
Phase 3
Phase 3 enrolling. Data due 2018.
CELG
$123.37
-0.45  (-0.36%)
GED-0301 (CD-003)
Crohn’s disease
Phase 3
Phase 3 enrolling. Data due 2018.
CELG
$123.37
-0.45  (-0.36%)
GED-0301 (CD-002)
Crohn’s disease
Phase 3
Phase 3 enrolling. Data due 2018.
CELG
$123.37
-0.45  (-0.36%)
CC-486 (Oral Azacitidine) - CC-486-AML-001
Post induction AML Maintenance
Phase 3
Phase 3 enrolling. Data due 2018.
CELG
$123.37
-0.45  (-0.36%)
ABRAXANE - NSCL-003 abound.sqm
First-line late stage Squamous Non-small cell lung cancer (NSCLC)
Phase 3
Phase 3 enrolling. Data due 2018.
CELG
$123.37
-0.45  (-0.36%)
ABRAXANE - IMpower 131 ( I/O Combo)
Non-small cell lung cancer (NSCLC)
Phase 3
Phase 3 data due 2018.
CELG
$123.37
-0.45  (-0.36%)
ABRAXANE - IMpower 130 ( I/O Combo)
Non-small cell lung cancer (NSCLC)
Phase 3
Phase 3 data due 2018.
CELG
$123.37
-0.45  (-0.36%)
ABRAXANE - IMPassion ( I/O Combo)
Triple Negative Metastatic Breast Cancer
Phase 3
Phase 3 data due 2018.
CELG
$123.37
-0.45  (-0.36%)
OTEZLA
Ulcerative Colitis
Phase 2
Phase 2 data due 2017. Phase 3 trial to be initiated 2018.
CLSN
$0.26
-0.02  (-5.39%)
ThermoDox - OPTIMA
Hepatocellular carcinoma - liver cancer
Phase 3
Failed to meet primary endpoint. New Phase 3 trial initiated, with enrollment to be completed early 2018 with first interim efficacy endpoint due 4Q 2018.
CNAT
$4.40
-0.02  (-0.45%)
Emricasan
NASH cirrhosis - ENCORE-PH trial
Phase 2
Phase 2b initiated November 2016. Data due 2018.
CNAT
$4.40
-0.02  (-0.45%)
Emricasan
NASH fibrosis - ENCORE-NF trial
Phase 2
Phase 2 trial initiated January 2016. Data are due 2018.
CRMD
$1.60
-0.16  (-9.09%)
Neutrolin - LOCK-IT 100
Hemodialysis patients with central venous catheters
Phase 3
Phase 3 enrollment to be completed 4Q 2017. Data due 2H 2018.
EARS
$0.90
-0.03  (-3.65%)
AM-111 ASSENT
Acute inner ear hearing loss
Phase 3
Phase 3 ASSENT data due 2H 2018.
FBIO
$3.43
-0.33  (-8.78%)
IV Tramadol
Post-operative Pain
Phase 3
Phase 3 to be initiated in 2017 with data due in 2018.
GSK
$39.31
0  (0%)
Closed Triple
Asthma
Phase 3
Phase 3 study completion due 2018.
IMGN
$3.61
-0.05  (-1.37%)
Kadcyla (KATHERINE).
HER2-positive breast cancer - residual invasive disease
Phase 3
Phase 3 data due in 2018.
INCY
$140.73
-7.79  (-5.25%)
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Phase 3
Phase 3 initiated June 2016. Initial data due 2018
INVA
$12.86
+0  (+0%)
Closed Triple
Asthma
Phase 3
Phase 3 study completion due 2018.
JNJ
$114.93
0  (0%)
STELARA (USTEKINUMAB)
Ulcerative colitis
Phase 3
Phase 3 trial to be completed in 2018.
JNJ
$114.93
0  (0%)
DARZALEX (Daratumumab)
Frontline multiple myeloma (non-transplant)
Phase 3
Phase 3 data likely due 2018.
KITE
$76.67
-8.27  (-9.74%)
KTE-C19 (ZUMA-2)
Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer
Phase 2
Phase 2 pivotal initiated November 2015. Data due 2018.
KITE
$76.67
-8.27  (-9.74%)
KTE-C19 (ZUMA-3)
Adult patients with r/r ALL - cancer
Phase 1/2
Phase 2 data due 2018.
KITE
$76.67
-8.27  (-9.74%)
KTE-C19 (ZUMA-4)
Pediatric and young adult patients with r/r ALL - cancer
Phase 1/2
Phase 2 data due 2018.
MACK
$3.02
-0.19  (-5.92%)
MM-121
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Phase 2
Phase 2 initiated mid Feb 2015. Data due by end of 2018.
MRK
$61.37
0  (0%)
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Phase 3
Phase 3 initiated June 2016. Initial data due 2018.
NVS
$71.95
0  (0%)
QVM149
Asthma
Phase 3
Phase 3 data due 2018.
NVS
$71.95
0  (0%)
Entresto - PIONEER
In-hospital initiation vs. enalapril following ADHF (acute decompensated heart failure)
Phase 3
Phase 3 trial completion due 2018.
NVS
$71.95
0  (0%)
Entresto - TRANSITION
Pre- vs. postdischarge initiation following ADHF (acute decompensated heart failure)
Phase 3
Phase 3 trial completion due 2018.
NVS
$71.95
0  (0%)
Entresto - PARAGON
HF-pEF (heart failure with preserved ejection fraction)
Phase 3
Phase 3 interim analysis due 2018. Filing 2019.
NVS
$71.95
0  (0%)
AIN457 (Cosentyx)
Non-radiographic axial SpA
Phase 3
Phase 3 data due 2018.
ONTX
$2.86
-0.05  (-1.72%)
IV Rigosertib - INSPIRE
2nd-line HR-MDS (high risk myelodysplastic syndromes)
Phase 3
Original Phase 3 trial did not meet endpoint in Feb 2014. However, following "subgroup analyses" and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Completion of trial expected in 2018.
PFE
$31.96
0  (0%)
Tanezumab
Cancer pain
Phase 3
Phase 3 ongoing. Estimate data due 2018 using clinicaltrials.gov data.
PLX
$1.10
-0.05  (-4.35%)
PRX-102
Fabry disease
Phase 3
Phase 3 dosing commenced October 2016. Enrollment to be completed 2H 2017 with data in 2018.
PRTO
$1.55
-0.1  (-6.06%)
Vonapanitase (PRT-201) PATENCY-2
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
Phase 3
Phase 3 enrollment to be completed 4Q 2017. Data due 4Q 2018.
RIGL
$2.72
-0.24  (-8.11%)
Fostamatinib
IgA nephropathy
Phase 2
Phase 2 preliminary data released January 5, 2017. Enrollment of second cohort to be completed in 2017 with data due in 2018.
SNGX
$2.35
-0.19  (-7.48%)
SGX203
Pediatric Crohn’s Disease
Phase 3
Phase 3 initiation due 1H 2017 with data due 2H 2018 - pending funding.
TBPH
$31.86
-1.87  (-5.54%)
Closed Triple
Asthma
Phase 3
Phase 3 study completion due 2018.
TBPH
$31.86
-1.87  (-5.54%)
Telavancin
Bacteremia
Phase 3
Phase 3 data due 2018
VNDA
$13.90
-0.25  (-1.77%)
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 3
Phase 3 initiated 4Q 2016. Data due 2018.
XNCR
$23.24
-1.15  (-4.72%)
XmAb5871
Systemic Lupus Erythematosus (SLE)
Phase 2
Phase 2 trial initiated March 2016. Initial data due 2018.
AGN
$233.99
-0.57  (-0.24%)
RAPASTINEL
Major depressive disorder (MDD)
Phase 3
Phase 3 initiated October 2016. Data due early 2019.
ABBV
$61.79
0  (0%)
ABBV-8E12
Progressive supranuclear palsy (PSP)
Phase 2
Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: May 2019
GBT
$36.30
-1.05  (-2.81%)
GBT440 - HOPE
Sickle cell disease in adults
Phase 3
Announced January 18, 2017 that Phase 3 enrollment has commenced. Previous guidance is for top-line data due 1H 2019.
NVS
$71.95
0  (0%)
Jakavi
Graft-versus-host disease (GVHD)
Phase 3
Phase 3 data and filing due 2019.
AKBA
$9.13
+0.17  (+1.9%)
Vadadustat - INNO2VATE
Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)
Phase 3
Phase 3 initiated August 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
AKBA
$9.13
+0.17  (+1.9%)
Vadadustat - PRO2TECT
Non-dialysis patients with anemia related to CKD (NDD-CKD)
Phase 3
Phase 3 initiated January 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
ALDX
$5.00
+0.05  (+1.01%)
NS2
Sjögren-Larsson Syndrome (SLS)
Phase 2
Phase 2 data released August 2016. Phase 3 trial to be initiated 2H 2017 with data due in 2019.
CELG
$123.37
-0.45  (-0.36%)
REVLIMID - MAGNIFY NHL-010
Untreated Activated B-Cell Diffuse large B-cell lymphoma (DLBCL)
Phase 3
Phase 3 data due 2019.
CELG
$123.37
-0.45  (-0.36%)
REVLIMID - MAGNIFY NHL-008
Relapsed or Refractory Indolent Lymphoma
Phase 3
Phase 3 data due 2019.
FOLD
$6.82
-0.44  (-6.13%)
Migalastat HCl monotherapy (012)
Fabry Disease
Phase 3
Additional trials required following feedback from FDA. Enrollment to commence 2017 with data due in 2019.
GILD
$71.93
0  (0%)
Filgotinib
Ulcerative Colitis
Phase 3
Phase 3 ongoing. Data due 2019 using clinicaltrials.gov data.
GILD
$71.93
0  (0%)
Filgotinib
Crohn's Disease
Phase 3
Phase 3 ongoing. Data due 2019 using clinicaltrials.gov data.
IMGN
$3.61
-0.05  (-1.37%)
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
Phase 3
Phase 3 data due in 2019.
JNJ
$114.93
0  (0%)
INVOKANA - CREDENCE
Diabetic Kidney Disease
Phase 3
Phase 3 data due 2019.
JNJ
$114.93
0  (0%)
DARZALEX (Daratumumab)
Frontline multiple myeloma (transplant)
Phase 3
Phase 3 data likely due 2019.
LLY
$76.76
0  (0%)
AZD3293
Early Alzheimer's disease
Phase 3
Phase 3 data due 2019.
MRK
$61.37
0  (0%)
MK-8931 (019) - Verubecestat
Mild-to-moderate Alzheimer's
Phase 3
Fully enrolled. Data due in 2019.
NVS
$71.95
0  (0%)
QAW039 (fevipiprant)
Asthma
Phase 3
Phase 3 data due 2019.
NVS
$71.95
0  (0%)
OMB157 (ofatumumab)
Relapsing multiple sclerosis
Phase 3
Phase 3 data due 2019.
NVS
$71.95
0  (0%)
Entresto - PARADISE
AMI (acute myocardial infarction)
Phase 3
Phase 3 trial completion due 2019. Filing 2020.
PFE
$31.96
0  (0%)
XTANDI (ENDEAR)
Triple negative breast cancer
Phase 3
Phase 3 ongoing. Estimate data 1H 2019 using clinicaltrials.gov data.
ABBV
$61.79
0  (0%)
ABBV-8E12
Alzheimer's disease
Phase 2
Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: April 2020.
OBSV
$11.32
+0.12  (+1.07%)
OBE2109 - PRIMROSE
Uterine fibroids
Phase 3